drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00553 | DB00595 | 92 | 1,545 | [
"DDInter1177",
"DDInter1374"
] | Methoxsalen | Oxytetracycline | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Moderate | 1 | [
[
[
92,
24,
1545
]
],
[
[
92,
63,
964
],
[
964,
1,
1545
]
],
[
[
92,
24,
753
],
[
753,
1,
1545
]
],
[
[
92,
24,
471
],
[
471,
62,
1545
]
],
[
[
92,
63,
1028
],
[
1028,
23,
1545
]
],
[
[
92,
24,
663
],
[
663,
24,
1545
]
],
[
[
92,
63,
612
],
[
612,
24,
1545
]
],
[
[
92,
63,
640
],
[
640,
25,
1545
]
],
[
[
92,
24,
1517
],
[
1517,
64,
1545
]
],
[
[
92,
63,
964
],
[
964,
1,
753
],
[
753,
1,
1545
]
]
] | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tigecycline"
],
[
"Tigecycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Verteporfin"
],
[
"Verteporfin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxytetracycline"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Tigecycline"
],
[
"Tigecycline",
"{u} (Compound) resembles {v} (Compound)",
"Oxytetracycline"
]
]
] | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Oxytetracycline (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Tigecycline and Tigecycline (Compound) resembles Oxytetracycline (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Acetazolamide and Acetazolamide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a minor interaction that can limit clinical effects when taken with Oxytetracycline
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Verteporfin and Verteporfin may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Oxytetracycline
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Oxytetracycline
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Tigecycline (Compound) and Tigecycline (Compound) resembles Oxytetracycline (Compound) |
DB00065 | DB14409 | 581 | 1,129 | [
"DDInter923",
"DDInter867"
] | Infliximab | Human adenovirus e serotype 4 strain cl-68578 antigen | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
581,
24,
1129
]
],
[
[
581,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
581,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
581,
25,
676
],
[
676,
63,
1129
]
],
[
[
581,
24,
599
],
[
599,
24,
1129
]
],
[
[
581,
64,
1057
],
[
1057,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
581,
25,
1683
],
[
1683,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
581,
64,
1184
],
[
1184,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
581,
24,
599
],
[
599,
63,
1057
],
[
1057,
24,
1129
]
],
[
[
581,
23,
1461
],
[
1461,
23,
76
],
[
76,
24,
1129
]
]
] | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Infliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mogamulizumab"
],
[
"Mogamulizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
]
] | Infliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may lead to a major life threatening interaction when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Infliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab and Mogamulizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen |
DB00446 | DB11767 | 597 | 1,583 | [
"DDInter351",
"DDInter1643"
] | Chloramphenicol | Sarilumab | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate. RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient. Subcutaneous administration of sarilumab has been shown to decrease acute-phase reactant levels and improve clinical RA symptoms. | Moderate | 1 | [
[
[
597,
24,
1583
]
],
[
[
597,
24,
1186
],
[
1186,
24,
1583
]
],
[
[
597,
63,
362
],
[
362,
24,
1583
]
],
[
[
597,
23,
1627
],
[
1627,
24,
1583
]
],
[
[
597,
24,
738
],
[
738,
63,
1583
]
],
[
[
597,
25,
975
],
[
975,
63,
1583
]
],
[
[
597,
25,
828
],
[
828,
24,
1583
]
],
[
[
597,
64,
1064
],
[
1064,
25,
1583
]
],
[
[
597,
24,
1683
],
[
1683,
25,
1583
]
],
[
[
597,
24,
676
],
[
676,
64,
1583
]
]
] | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
],
[
"Radium Ra 223 dichloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
]
]
] | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride and Radium Ra 223 dichloride may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Chloramphenicol may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Chloramphenicol may lead to a major life threatening interaction when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Chloramphenicol may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sarilumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Sarilumab
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Sarilumab |
DB00722 | DB01284 | 743 | 1,042 | [
"DDInter1079",
"DDInter1782"
] | Lisinopril | Tetracosactide | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Moderate | 1 | [
[
[
743,
24,
1042
]
],
[
[
743,
24,
761
],
[
761,
63,
1042
]
],
[
[
743,
35,
1144
],
[
1144,
24,
1042
]
],
[
[
743,
40,
1638
],
[
1638,
24,
1042
]
],
[
[
743,
1,
610
],
[
610,
24,
1042
]
],
[
[
743,
63,
590
],
[
590,
24,
1042
]
],
[
[
743,
24,
123
],
[
123,
24,
1042
]
],
[
[
743,
23,
286
],
[
286,
63,
1042
]
],
[
[
743,
24,
593
],
[
593,
25,
1042
]
],
[
[
743,
25,
1377
],
[
1377,
25,
1042
]
]
] | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Trandolapril"
],
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} (Compound) resembles {v} (Compound)",
"Enalapril"
],
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Lisinopril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
]
] | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril (Compound) resembles Nateglinide (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril (Compound) resembles Trandolapril (Compound) and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril (Compound) resembles Enalapril (Compound) and Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Tetracosactide
Lisinopril may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tetracosactide |
DB00358 | DB09078 | 1,010 | 1,228 | [
"DDInter1140",
"DDInter1036"
] | Mefloquine | Lenvatinib | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
1010,
24,
1228
]
],
[
[
1010,
23,
112
],
[
112,
23,
1228
]
],
[
[
1010,
24,
463
],
[
463,
23,
1228
]
],
[
[
1010,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
1010,
24,
938
],
[
938,
63,
1228
]
],
[
[
1010,
24,
609
],
[
609,
24,
1228
]
],
[
[
1010,
64,
534
],
[
534,
24,
1228
]
],
[
[
1010,
25,
1069
],
[
1069,
25,
1228
]
],
[
[
1010,
64,
1176
],
[
1176,
25,
1228
]
],
[
[
1010,
25,
982
],
[
982,
64,
1228
]
]
] | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
] | Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Rifampicin and Rifampicin may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mefloquine may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Mefloquine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Mefloquine may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Lenvatinib
Mefloquine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lenvatinib |
DB08868 | DB09351 | 1,011 | 722 | [
"DDInter737",
"DDInter1048"
] | Fingolimod | Levobetaxolol (ophthalmic) | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657] | (S)-betaxolol is the (S)-enantiomer of betaxolol. It is an enantiomer of a (R)-betaxolol. | Moderate | 1 | [
[
[
1011,
24,
722
]
],
[
[
1011,
24,
1276
],
[
1276,
63,
722
]
],
[
[
1011,
64,
1593
],
[
1593,
24,
722
]
],
[
[
1011,
25,
1476
],
[
1476,
63,
722
]
],
[
[
1011,
24,
1276
],
[
1276,
63,
770
],
[
770,
24,
722
]
],
[
[
1011,
64,
1593
],
[
1593,
63,
770
],
[
770,
24,
722
]
],
[
[
1011,
64,
770
],
[
770,
24,
1276
],
[
1276,
63,
722
]
],
[
[
1011,
64,
1053
],
[
1053,
64,
770
],
[
770,
24,
722
]
],
[
[
1011,
25,
1476
],
[
1476,
63,
1276
],
[
1276,
63,
722
]
],
[
[
1011,
64,
699
],
[
699,
62,
27
],
[
27,
23,
722
]
]
] | [
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
],
[
"Alectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levobetaxolol"
]
],
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glucagon"
],
[
"Glucagon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levobetaxolol"
]
]
] | Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Alectinib and Alectinib may cause a moderate interaction that could exacerbate diseases when taken with Levobetaxolol
Fingolimod may lead to a major life threatening interaction when taken with Nadolol and Nadolol may cause a minor interaction that can limit clinical effects when taken with Glucagon and Glucagon may cause a minor interaction that can limit clinical effects when taken with Levobetaxolol |
DB00006 | DB01268 | 942 | 1,151 | [
"DDInter217",
"DDInter1731"
] | Bivalirudin | Sunitinib | Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure. | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Moderate | 1 | [
[
[
942,
24,
1151
]
],
[
[
942,
24,
758
],
[
758,
24,
1151
]
],
[
[
942,
25,
235
],
[
235,
63,
1151
]
],
[
[
942,
25,
1213
],
[
1213,
24,
1151
]
],
[
[
942,
64,
1578
],
[
1578,
24,
1151
]
],
[
[
942,
25,
702
],
[
702,
25,
1151
]
],
[
[
942,
24,
318
],
[
318,
25,
1151
]
],
[
[
942,
25,
1650
],
[
1650,
64,
1151
]
],
[
[
942,
24,
758
],
[
758,
24,
1311
],
[
1311,
1,
1151
]
],
[
[
942,
25,
235
],
[
235,
63,
758
],
[
758,
24,
1151
]
]
] | [
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) resembles {v} (Compound)",
"Sunitinib"
]
],
[
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
]
]
] | Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Bivalirudin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Bivalirudin may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib
Bivalirudin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Sunitinib
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may lead to a major life threatening interaction when taken with Sunitinib
Bivalirudin may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Sunitinib
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) resembles Sunitinib (Compound)
Bivalirudin may lead to a major life threatening interaction when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib |
DB01041 | DB11859 | 770 | 418 | [
"DDInter1789",
"DDInter230"
] | Thalidomide | Brexanolone | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence. | As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically for the treatment of postpartum depression (PPD) in adult females . Since PPD, like various other types of depression, is characterized by feelings of sadness, worthlessness or guilt, cognitive impairment, and/or possibly suicidal ideation, it is considered a life-threatening condition . Studies have consequently found that PPD can genuinely have profound negative effects on the maternal-infant bond and later infant development [F4072, A176080, A176083]. The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before . In particular, the use of brexanolone in treating PPD is surrounded with promise because it acts in part as a synthetic supplement for possible deficiencies in endogenous brexanolone (allopregnanolone) in postpartum women susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do not mediate activities directly associated with PPD like natural fluctuations in the levels of endogenous neuroactive steroids like allopregnanolone . And finally, although brexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare success in the weaning of third-line agents and resolution of potentially life-threatening status epilepticus with brexanolone vs. placebo when added to standard-of-care . | Moderate | 1 | [
[
[
770,
24,
418
]
],
[
[
770,
24,
820
],
[
820,
24,
418
]
],
[
[
770,
63,
100
],
[
100,
24,
418
]
],
[
[
770,
64,
1648
],
[
1648,
24,
418
]
],
[
[
770,
25,
1053
],
[
1053,
24,
418
]
],
[
[
770,
24,
820
],
[
820,
63,
100
],
[
100,
24,
418
]
],
[
[
770,
63,
100
],
[
100,
24,
820
],
[
820,
24,
418
]
],
[
[
770,
63,
104
],
[
104,
40,
820
],
[
820,
24,
418
]
],
[
[
770,
24,
401
],
[
401,
24,
820
],
[
820,
24,
418
]
],
[
[
770,
64,
1648
],
[
1648,
24,
820
],
[
820,
24,
418
]
]
] | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
],
[
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexanolone"
]
]
] | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone
Thalidomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Brexanolone |
DB00593 | DB09065 | 1,464 | 760 | [
"DDInter695",
"DDInter424"
] | Ethosuximide | Cobicistat | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Moderate | 1 | [
[
[
1464,
24,
760
]
],
[
[
1464,
63,
1101
],
[
1101,
23,
760
]
],
[
[
1464,
24,
723
],
[
723,
24,
760
]
],
[
[
1464,
63,
506
],
[
506,
24,
760
]
],
[
[
1464,
24,
1619
],
[
1619,
63,
760
]
],
[
[
1464,
24,
1017
],
[
1017,
64,
760
]
],
[
[
1464,
24,
1478
],
[
1478,
25,
760
]
],
[
[
1464,
63,
1101
],
[
1101,
24,
479
],
[
479,
23,
760
]
],
[
[
1464,
24,
723
],
[
723,
23,
479
],
[
479,
23,
760
]
],
[
[
1464,
24,
1040
],
[
1040,
63,
479
],
[
479,
23,
760
]
]
] | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
]
] | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may lead to a major life threatening interaction when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat |
DB00197 | DB09330 | 1,324 | 985 | [
"DDInter1881",
"DDInter1352"
] | Troglitazone | Osimertinib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Moderate | 1 | [
[
[
1324,
24,
985
]
],
[
[
1324,
63,
168
],
[
168,
23,
985
]
],
[
[
1324,
23,
608
],
[
608,
23,
985
]
],
[
[
1324,
24,
1478
],
[
1478,
24,
985
]
],
[
[
1324,
24,
1598
],
[
1598,
63,
985
]
],
[
[
1324,
23,
1101
],
[
1101,
24,
985
]
],
[
[
1324,
25,
990
],
[
990,
24,
985
]
],
[
[
1324,
24,
11
],
[
11,
25,
985
]
],
[
[
1324,
24,
484
],
[
484,
64,
985
]
],
[
[
1324,
25,
1510
],
[
1510,
25,
985
]
]
] | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Troglitazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Troglitazone may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Osimertinib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Osimertinib
Troglitazone may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Osimertinib |
DB01211 | DB08903 | 609 | 996 | [
"DDInter393",
"DDInter170"
] | Clarithromycin | Bedaquiline | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Bedaquiline is a bactericidal antimycobacterial drug belonging to the class of diarylquinoline. The quinolinic central heterocyclic nucleus with alcohol and amine side chains is responsible for bedaquiline-mediated antimycobacterial activity. Although it is closely related to fluoroquinolones, bedaquiline does not affect DNA gyrase; instead, bedaquiline inhibits the c subunit of ATP synthase responsible for synthesizing ATP. Consequently, bedaquiline can be used to treat mycobacterial infection, particularly tuberculosis (TB). Although the current standard of TB treatment of anti-TB drugs for 2 months, including 2 key drugs [isoniazid] and [rifampin], is highly effective, the emergence of multidrug-resistant TB (MDR-TB) to [isoniazid] and [rifampin] has substantially worsened patients outcome. Bedaquiline was approved by the FDA on December 28, 2012, to treat pulmonary MDR-TB, following favorable results in multiple pre-clinical and clinical studies.[A261856,A261861] It is the first drug that was approved in the last 40 years by the FDA for TB unresponsive to current treatments on the market. Currently, bedaquiline is the last-line anti-TB drug and must only be used in an appropriate combination regimen.[L48506,A261866] | Major | 2 | [
[
[
609,
25,
996
]
],
[
[
609,
6,
8374
],
[
8374,
45,
996
]
],
[
[
609,
21,
29267
],
[
29267,
60,
996
]
],
[
[
609,
62,
112
],
[
112,
23,
996
]
],
[
[
609,
24,
26
],
[
26,
63,
996
]
],
[
[
609,
63,
355
],
[
355,
24,
996
]
],
[
[
609,
25,
283
],
[
283,
63,
996
]
],
[
[
609,
24,
1047
],
[
1047,
24,
996
]
],
[
[
609,
64,
467
],
[
467,
24,
996
]
],
[
[
609,
25,
263
],
[
263,
24,
996
]
]
] | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Alanine aminotransferase increased"
],
[
"Alanine aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]
]
] | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bedaquiline (Compound)
Clarithromycin (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Bedaquiline (Compound)
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bedaquiline
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Clarithromycin may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Clarithromycin may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline
Clarithromycin may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline |
DB08870 | DB08913 | 850 | 1,186 | [
"DDInter228",
"DDInter1561"
] | Brentuximab vedotin | Radium Ra 223 dichloride | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm. | Moderate | 1 | [
[
[
850,
24,
1186
]
],
[
[
850,
63,
37
],
[
37,
24,
1186
]
],
[
[
850,
24,
1583
],
[
1583,
63,
1186
]
],
[
[
850,
64,
329
],
[
329,
24,
1186
]
],
[
[
850,
25,
1510
],
[
1510,
24,
1186
]
],
[
[
850,
24,
1468
],
[
1468,
24,
1186
]
],
[
[
850,
25,
1259
],
[
1259,
63,
1186
]
],
[
[
850,
63,
1374
],
[
1374,
25,
1186
]
],
[
[
850,
63,
37
],
[
37,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
850,
24,
1583
],
[
1583,
63,
134
],
[
134,
24,
1186
]
]
] | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bleomycin"
],
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Radium Ra 223 dichloride"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
]
] | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Brentuximab vedotin may lead to a major life threatening interaction when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Brentuximab vedotin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Brentuximab vedotin may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may lead to a major life threatening interaction when taken with Radium Ra 223 dichloride
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride |
DB00073 | DB00092 | 1,394 | 58 | [
"DDInter1608",
"DDInter40"
] | Rituximab | Alefacept | Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences, [FDA label]. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL), however, has now been approved for a variety of conditions [FDA label]. On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab). | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Moderate | 1 | [
[
[
1394,
24,
58
]
],
[
[
1394,
23,
1114
],
[
1114,
62,
58
]
],
[
[
1394,
24,
949
],
[
949,
63,
58
]
],
[
[
1394,
24,
599
],
[
599,
24,
58
]
],
[
[
1394,
25,
980
],
[
980,
63,
58
]
],
[
[
1394,
63,
1184
],
[
1184,
24,
58
]
],
[
[
1394,
64,
1057
],
[
1057,
24,
58
]
],
[
[
1394,
25,
676
],
[
676,
64,
58
]
],
[
[
1394,
23,
1114
],
[
1114,
23,
994
],
[
994,
63,
58
]
],
[
[
1394,
23,
1461
],
[
1461,
24,
329
],
[
329,
63,
58
]
]
] | [
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc sulfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Risankizumab"
],
[
"Risankizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Rituximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
],
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
]
] | Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Alefacept
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Rituximab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Rituximab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Rituximab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Rituximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Alefacept
Rituximab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Risankizumab and Risankizumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Rituximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept |
DB00501 | DB00697 | 752 | 876 | [
"DDInter380",
"DDInter1821"
] | Cimetidine | Tizanidine | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury . It may also be caused by musculoskeletal injury . Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label]. | Major | 2 | [
[
[
752,
25,
876
]
],
[
[
752,
6,
7950
],
[
7950,
45,
876
]
],
[
[
752,
21,
28882
],
[
28882,
60,
876
]
],
[
[
752,
23,
112
],
[
112,
62,
876
]
],
[
[
752,
24,
770
],
[
770,
63,
876
]
],
[
[
752,
25,
1213
],
[
1213,
63,
876
]
],
[
[
752,
62,
1424
],
[
1424,
24,
876
]
],
[
[
752,
23,
609
],
[
609,
63,
876
]
],
[
[
752,
25,
888
],
[
888,
24,
876
]
],
[
[
752,
64,
322
],
[
322,
24,
876
]
]
] | [
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
]
]
] | Cimetidine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Tizanidine (Compound)
Cimetidine (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Tizanidine (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tizanidine
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Cimetidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Cimetidine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine
Cimetidine may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine |
DB06605 | DB11791 | 1,409 | 785 | [
"DDInter108",
"DDInter287"
] | Apixaban | Capmatinib | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways such as STAT3, PI3K/ATK, and RAS/MAPK. Mutations in _MET_ have been detected in non-small cell lung cancer (NSCLC), and the prevalence of _MET_ amplification in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-naive patients with NSCLC has been reported to be 1.4% - 21%. This co-occurrence has made c-Met a desirable target in the treatment of NSCLC. Manufactured by Novartis and marketed under the brand name Tabrecta, capmatinib was granted accelerated approval by the FDA on May 6, 2020, for the treatment of NSCLC in patients whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. The presence of the mutation must be confirmed by an FDA-approved test, such as the FoundationOne CDx assay (manufactured by Foundation Medicine, Inc.), which was approved by the FDA on the same day. As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials. Capmatinib was approved by Health Canada on June 8, 2022. | Moderate | 1 | [
[
[
1409,
24,
785
]
],
[
[
1409,
63,
1324
],
[
1324,
24,
785
]
],
[
[
1409,
24,
868
],
[
868,
24,
785
]
],
[
[
1409,
24,
1320
],
[
1320,
63,
785
]
],
[
[
1409,
64,
126
],
[
126,
24,
785
]
],
[
[
1409,
25,
578
],
[
578,
24,
785
]
],
[
[
1409,
25,
1421
],
[
1421,
63,
785
]
],
[
[
1409,
24,
1017
],
[
1017,
64,
785
]
],
[
[
1409,
25,
1604
],
[
1604,
25,
785
]
],
[
[
1409,
63,
1220
],
[
1220,
25,
785
]
]
] | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Capmatinib"
]
]
] | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Apixaban may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Apixaban may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Apixaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Capmatinib
Apixaban may lead to a major life threatening interaction when taken with Lumacaftor and Lumacaftor may lead to a major life threatening interaction when taken with Capmatinib
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Capmatinib |
DB01222 | DB09082 | 617 | 659 | [
"DDInter246",
"DDInter1934"
] | Budesonide | Vilanterol | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Minor | 0 | [
[
[
617,
23,
659
]
],
[
[
617,
40,
1220
],
[
1220,
23,
659
]
],
[
[
617,
63,
88
],
[
88,
24,
659
]
],
[
[
617,
25,
1155
],
[
1155,
63,
659
]
],
[
[
617,
24,
1375
],
[
1375,
63,
659
]
],
[
[
617,
64,
1091
],
[
1091,
24,
659
]
],
[
[
617,
62,
1674
],
[
1674,
24,
659
]
],
[
[
617,
24,
1250
],
[
1250,
24,
659
]
],
[
[
617,
23,
1032
],
[
1032,
63,
659
]
],
[
[
617,
25,
384
],
[
384,
24,
659
]
]
] | [
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
]
] | Budesonide (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may lead to a major life threatening interaction when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Budesonide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol |
DB01042 | DB10276 | 1,307 | 1,624 | [
"DDInter1144",
"DDInter1623"
] | Melphalan | Rotavirus vaccine | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection. | Major | 2 | [
[
[
1307,
25,
1624
]
],
[
[
1307,
63,
552
],
[
552,
25,
1624
]
],
[
[
1307,
64,
770
],
[
770,
25,
1624
]
],
[
[
1307,
62,
322
],
[
322,
25,
1624
]
],
[
[
1307,
25,
375
],
[
375,
25,
1624
]
],
[
[
1307,
24,
1488
],
[
1488,
25,
1624
]
],
[
[
1307,
24,
270
],
[
270,
64,
1624
]
],
[
[
1307,
25,
1259
],
[
1259,
64,
1624
]
],
[
[
1307,
63,
552
],
[
552,
63,
1648
],
[
1648,
25,
1624
]
],
[
[
1307,
63,
1648
],
[
1648,
24,
617
],
[
617,
24,
1624
]
]
] | [
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Melphalan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
]
] | Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may cause a minor interaction that can limit clinical effects when taken with Epirubicin and Epirubicin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine |
DB09075 | DB14276 | 498 | 1,631 | [
"DDInter621",
"DDInter1892"
] | Edoxaban | Turmeric | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and | Turmeric is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Minor | 0 | [
[
[
498,
23,
1631
]
],
[
[
498,
64,
20
],
[
20,
23,
1631
]
],
[
[
498,
25,
1421
],
[
1421,
23,
1631
]
],
[
[
498,
64,
20
],
[
20,
24,
1018
],
[
1018,
23,
1631
]
],
[
[
498,
64,
1018
],
[
1018,
63,
20
],
[
20,
23,
1631
]
],
[
[
498,
64,
1578
],
[
1578,
25,
20
],
[
20,
23,
1631
]
],
[
[
498,
64,
500
],
[
500,
64,
20
],
[
20,
23,
1631
]
],
[
[
498,
25,
1421
],
[
1421,
64,
20
],
[
20,
23,
1631
]
],
[
[
498,
23,
297
],
[
297,
62,
20
],
[
20,
23,
1631
]
],
[
[
498,
63,
758
],
[
758,
63,
20
],
[
20,
23,
1631
]
]
] | [
[
[
"Edoxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
],
[
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
]
]
] | Edoxaban may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Tenecteplase and Tenecteplase may cause a minor interaction that can limit clinical effects when taken with Turmeric |
DB01105 | DB06209 | 222 | 256 | [
"DDInter1665",
"DDInter1508"
] | Sibutramine | Prasugrel | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009. | Moderate | 1 | [
[
[
222,
24,
256
]
],
[
[
222,
6,
8374
],
[
8374,
45,
256
]
],
[
[
222,
21,
28681
],
[
28681,
60,
256
]
],
[
[
222,
62,
752
],
[
752,
23,
256
]
],
[
[
222,
25,
593
],
[
593,
23,
256
]
],
[
[
222,
64,
1161
],
[
1161,
23,
256
]
],
[
[
222,
63,
188
],
[
188,
23,
256
]
],
[
[
222,
25,
901
],
[
901,
24,
256
]
],
[
[
222,
63,
421
],
[
421,
24,
256
]
],
[
[
222,
25,
1427
],
[
1427,
63,
256
]
]
] | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
],
[
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prasugrel"
]
]
] | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound)
Sibutramine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Prasugrel (Compound)
Sibutramine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Sibutramine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Sibutramine may lead to a major life threatening interaction when taken with Selegiline and Selegiline may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Nevirapine and Nevirapine may cause a minor interaction that can limit clinical effects when taken with Prasugrel
Sibutramine may lead to a major life threatening interaction when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel
Sibutramine may lead to a major life threatening interaction when taken with Vortioxetine and Vortioxetine may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel |
DB00384 | DB00620 | 1,275 | 175 | [
"DDInter1859",
"DDInter1855"
] | Triamterene | Triamcinolone | Triamterene (2,4,7-triamino-6-phenylpteridine) is a potassium-sparing diuretic that is used in the management of hypertension. It works by promoting the excretion of sodium ions and water while decreasing the potassium excretion in the distal part of the nephron in the kidneys by working on the lumenal side. Since it acts on the distal nephron where only a small fraction of sodium ion reabsorption occurs, triamterene is reported to have limited diuretic efficacy. Due to its effects on increased serum potassium levels, triamterene is associated with a risk of producing hyperkalemia. Triamterene is a weak antagonist of folic acid, and a photosensitizing drug. Triamterene was approved by the Food and Drug Administration in the U.S. in 1964. Currently, triamterene is used in the treatment of edema associated with various | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermatoses. Triamcinolone is more commonly seen in the forms triamcinolone hexacetonide, triamcinolone acetonide, and triamcinolone diacetate.[L8246,L8249,L8252,L8255,L8258,L8261,L8264] Triamcinolone was granted FDA approval on 3 December 1957. In October 2021, a suspension of triamcinolone acetonide was approved for suprachoroidal injection - the first suprachoroidal injection to receive FDA approval - for the treatment of patients with macular edema associated with uveitis. | Moderate | 1 | [
[
[
1275,
24,
175
]
],
[
[
1275,
24,
1573
],
[
1573,
1,
175
]
],
[
[
1275,
24,
617
],
[
617,
40,
175
]
],
[
[
1275,
7,
7720
],
[
7720,
45,
175
]
],
[
[
1275,
21,
28762
],
[
28762,
60,
175
]
],
[
[
1275,
24,
720
],
[
720,
63,
175
]
],
[
[
1275,
63,
1645
],
[
1645,
24,
175
]
],
[
[
1275,
24,
355
],
[
355,
24,
175
]
],
[
[
1275,
24,
497
],
[
497,
64,
175
]
],
[
[
1275,
24,
1573
],
[
1573,
1,
11375
],
[
11375,
1,
175
]
]
] | [
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
],
[
"Mineral oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triamcinolone"
]
],
[
[
"Triamterene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Desoximetasone"
],
[
"Desoximetasone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
]
]
] | Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Triamcinolone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Budesonide and Budesonide (Compound) resembles Triamcinolone (Compound)
Triamterene (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Triamcinolone (Compound)
Triamterene (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Triamcinolone (Compound)
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil and Mineral oil may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Triamcinolone
Triamterene may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Desoximetasone (Compound) and Desoximetasone (Compound) resembles Triamcinolone (Compound) |
DB00224 | DB00448 | 215 | 1,215 | [
"DDInter917",
"DDInter1022"
] | Indinavir | Lansoprazole | A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem] | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux disease (GERD) along with other pathologies caused by excessive acid secretion. | Moderate | 1 | [
[
[
215,
24,
1215
]
],
[
[
215,
24,
379
],
[
379,
1,
1215
]
],
[
[
215,
63,
837
],
[
837,
1,
1215
]
],
[
[
215,
6,
8374
],
[
8374,
45,
1215
]
],
[
[
215,
21,
28882
],
[
28882,
60,
1215
]
],
[
[
215,
25,
263
],
[
263,
62,
1215
]
],
[
[
215,
25,
629
],
[
629,
63,
1215
]
],
[
[
215,
63,
1324
],
[
1324,
24,
1215
]
],
[
[
215,
24,
129
],
[
129,
63,
1215
]
],
[
[
215,
40,
1327
],
[
1327,
63,
1215
]
]
] | [
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
],
[
[
"Indinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
]
]
] | Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound)
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Lansoprazole (Compound)
Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lansoprazole (Compound)
Indinavir (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Lansoprazole (Compound)
Indinavir may lead to a major life threatening interaction when taken with Axitinib and Axitinib may cause a minor interaction that can limit clinical effects when taken with Lansoprazole
Indinavir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Indinavir may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole
Indinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole |
DB00454 | DB06691 | 1,349 | 849 | [
"DDInter1150",
"DDInter1155"
] | Meperidine | Mepyramine | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescription medication used for cough, cold, or allergic conditions. | Moderate | 1 | [
[
[
1349,
24,
849
]
],
[
[
1349,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1349,
24,
272
],
[
272,
24,
849
]
],
[
[
1349,
6,
12523
],
[
12523,
45,
849
]
],
[
[
1349,
24,
412
],
[
412,
63,
849
]
],
[
[
1349,
40,
411
],
[
411,
24,
849
]
],
[
[
1349,
64,
475
],
[
475,
24,
849
]
],
[
[
1349,
25,
1053
],
[
1053,
24,
849
]
],
[
[
1349,
24,
662
],
[
662,
35,
849
]
],
[
[
1349,
63,
1594
],
[
1594,
1,
11775
],
[
11775,
40,
849
]
]
] | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Remifentanil"
],
[
"Remifentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Chloropyramine"
],
[
"Chloropyramine",
"{u} (Compound) resembles {v} (Compound)",
"Mepyramine"
]
]
] | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Mepyramine (Compound)
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline and Eluxadoline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine (Compound) resembles Remifentanil (Compound) and Remifentanil may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mepyramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Chloropyramine (Compound) and Chloropyramine (Compound) resembles Mepyramine (Compound) |
DB00163 | DB01024 | 1,461 | 1,096 | [
"DDInter1943",
"DDInter1252"
] | Vitamin E | Mycophenolic acid | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are currently being researched for use in the treatment of diseases causing bone loss, cardiovascular diseases, diabetes mellitus and associated comorbidities, eye diseases, inflammatory diseases (including skin conditions), lipid disorders, neurological diseases, and radiation damage. Though this research is so far inconclusive, vitamin E remains a popular supplement and is generally considered safe by the FDA[FDA Label]. | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. [Mycophenolate mofetil], a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection. | Minor | 0 | [
[
[
1461,
23,
1096
]
],
[
[
1461,
18,
15501
],
[
15501,
57,
1096
]
],
[
[
1461,
24,
428
],
[
428,
62,
1096
]
],
[
[
1461,
24,
965
],
[
965,
24,
1096
]
],
[
[
1461,
23,
270
],
[
270,
63,
1096
]
],
[
[
1461,
23,
629
],
[
629,
24,
1096
]
],
[
[
1461,
62,
58
],
[
58,
24,
1096
]
],
[
[
1461,
24,
1064
],
[
1064,
25,
1096
]
],
[
[
1461,
23,
375
],
[
375,
64,
1096
]
],
[
[
1461,
62,
581
],
[
581,
25,
1096
]
]
] | [
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
],
[
"Ferrous fumarate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sevelamer"
],
[
"Sevelamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mycophenolic acid"
]
]
] | Vitamin E (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Mycophenolic acid (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate and Ferrous fumarate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Sevelamer and Sevelamer may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Mycophenolic acid
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Mycophenolic acid
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Mycophenolic acid |
DB01268 | DB12332 | 1,151 | 1,619 | [
"DDInter1731",
"DDInter1626"
] | Sunitinib | Rucaparib | Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1151,
24,
1619
]
],
[
[
1151,
63,
307
],
[
307,
23,
1619
]
],
[
[
1151,
62,
112
],
[
112,
23,
1619
]
],
[
[
1151,
63,
87
],
[
87,
24,
1619
]
],
[
[
1151,
24,
1662
],
[
1662,
24,
1619
]
],
[
[
1151,
24,
159
],
[
159,
63,
1619
]
],
[
[
1151,
25,
913
],
[
913,
24,
1619
]
],
[
[
1151,
64,
1101
],
[
1101,
24,
1619
]
],
[
[
1151,
62,
1247
],
[
1247,
24,
1619
]
],
[
[
1151,
25,
503
],
[
503,
63,
1619
]
]
] | [
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sunitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sunitinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sunitinib may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sunitinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sunitinib may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB08865 | DB15035 | 1,593 | 503 | [
"DDInter448",
"DDInter1959"
] | Crizotinib | Zanubrutinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long-term survival. BTK is an enzyme that plays a role in oncogenic signalling pathways, promoting the survival and proliferation of malignant B cells. Compared to the first-generation BTK inhibitor [ibrutinib], zanubrutinib displays higher potency and selectivity for BTK with fewer off-target effects. Due to this enhanced selectivity towards BTK, zanubrutinib belongs to the second-generation BTK inhibitor drug group that also includes [acalabrutinib], which was approved by the FDA in 2017. Zanubrutinib was granted accelerated approval by the FDA in November 2019 based on clinical trial results that demonstrated an 84% overall response rate from zanubrutinib therapy in patients with MCL, which measures the proportion of patients in a trial whose tumour is entirely or partially destroyed by a drug. It is currently marketed under the trade name BRUKINSA™ and is available as oral capsules. In August 2021, the FDA granted accelerated approval to zanubrutinib for the treatment of adults with Waldenström’s macroglobulinemia. This indication is valid in the US, Europe, and Canada. In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended zanubrutinib be granted marketing authorization for the treatment of chronic lymphocytic leukemia. | Major | 2 | [
[
[
1593,
25,
503
]
],
[
[
1593,
24,
1094
],
[
1094,
24,
503
]
],
[
[
1593,
25,
982
],
[
982,
24,
503
]
],
[
[
1593,
63,
1324
],
[
1324,
24,
503
]
],
[
[
1593,
64,
1478
],
[
1478,
24,
503
]
],
[
[
1593,
64,
39
],
[
39,
25,
503
]
],
[
[
1593,
24,
676
],
[
676,
64,
503
]
],
[
[
1593,
25,
1618
],
[
1618,
25,
503
]
],
[
[
1593,
24,
976
],
[
976,
25,
503
]
],
[
[
1593,
63,
1419
],
[
1419,
25,
503
]
]
] | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
],
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
]
]
] | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Crizotinib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Crizotinib may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Crizotinib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Zanubrutinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Zanubrutinib
Crizotinib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Zanubrutinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Zanubrutinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Zanubrutinib |
DB00601 | DB01064 | 453 | 1,148 | [
"DDInter1073",
"DDInter987"
] | Linezolid | Isoprenaline | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the initiation of bacterial protein synthesis - more specifically, it binds to the 23S ribosomal RNA of the 50S subunit[A11227,A199050] and, in doing so, prevents the formation of the 70S initiation complex which is essential for bacterial reproduction. Linezolid was initially approved in 2000 and was the first member of the oxazolidinone antibiotic class. A second member of this class, [tedizolid], was approved by the FDA in 2014 and is considered generally more effective and tolerable than its predecessor. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Moderate | 1 | [
[
[
453,
24,
1148
]
],
[
[
453,
64,
1636
],
[
1636,
24,
1148
]
],
[
[
453,
24,
480
],
[
480,
24,
1148
]
],
[
[
453,
25,
874
],
[
874,
24,
1148
]
],
[
[
453,
21,
28695
],
[
28695,
60,
1148
]
],
[
[
453,
24,
959
],
[
959,
63,
1148
]
],
[
[
453,
25,
1629
],
[
1629,
63,
1148
]
],
[
[
453,
63,
1179
],
[
1179,
24,
1148
]
],
[
[
453,
37,
1090
],
[
1090,
63,
1148
]
],
[
[
453,
25,
1166
],
[
1166,
25,
1148
]
]
] | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Tetryzoline"
],
[
"Tetryzoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
]
]
] | Linezolid may lead to a major life threatening interaction when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid may lead to a major life threatening interaction when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Isoprenaline (Compound)
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Linezolid may lead to a major life threatening interaction when taken with Tetryzoline and Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Linezolid may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Isoprenaline |
DB11652 | DB11718 | 1,155 | 927 | [
"DDInter1891",
"DDInter640"
] | Tucatinib | Encorafenib | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and secretion. Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin lymphoma, colorectal cancer, thyroid carcinoma, non-small cell lung carcinoma, hairy cell leukemia and adenocarcinoma of the lung. On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. | Major | 2 | [
[
[
1155,
25,
927
]
],
[
[
1155,
63,
1088
],
[
1088,
24,
927
]
],
[
[
1155,
64,
1491
],
[
1491,
24,
927
]
],
[
[
1155,
25,
484
],
[
484,
63,
927
]
],
[
[
1155,
62,
1101
],
[
1101,
24,
927
]
],
[
[
1155,
24,
1320
],
[
1320,
63,
927
]
],
[
[
1155,
24,
1499
],
[
1499,
24,
927
]
],
[
[
1155,
25,
1017
],
[
1017,
64,
927
]
],
[
[
1155,
64,
39
],
[
39,
25,
927
]
],
[
[
1155,
63,
723
],
[
723,
25,
927
]
]
] | [
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifaximin"
],
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Tucatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
]
] | Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Rifaximin and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Tucatinib may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Tucatinib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Tucatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Tucatinib may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Encorafenib
Tucatinib may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Encorafenib
Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Encorafenib |
DB00222 | DB09068 | 245 | 1,427 | [
"DDInter825",
"DDInter1948"
] | Glimepiride | Vortioxetine | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression. | Moderate | 1 | [
[
[
245,
24,
1427
]
],
[
[
245,
63,
1685
],
[
1685,
24,
1427
]
],
[
[
245,
24,
1604
],
[
1604,
63,
1427
]
],
[
[
245,
24,
1220
],
[
1220,
24,
1427
]
],
[
[
245,
40,
959
],
[
959,
24,
1427
]
],
[
[
245,
23,
1051
],
[
1051,
24,
1427
]
],
[
[
245,
24,
1264
],
[
1264,
25,
1427
]
],
[
[
245,
63,
73
],
[
73,
25,
1427
]
],
[
[
245,
63,
1685
],
[
1685,
24,
1220
],
[
1220,
24,
1427
]
],
[
[
245,
24,
1604
],
[
1604,
63,
477
],
[
477,
24,
1427
]
]
] | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
],
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
]
] | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Glimepiride may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Vortioxetine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Vortioxetine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor and Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine |
DB06168 | DB09322 | 1,531 | 1,114 | [
"DDInter281",
"DDInter1966"
] | Canakinumab | Zinc sulfate | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. Both heavy chains of canakinumab contain oligosaccharide chains linked to the protein backbone at asparagine 298 (Asn 298). Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra). Canakinumab is marketed under the brand name Ilaris and indicated for patients 4 years of age and older to treat Familial | Zinc sulfate is the inorganic compound with the formula ZnSO4 and historically known as "white vitriol". It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system. | Minor | 0 | [
[
[
1531,
23,
1114
]
],
[
[
1531,
63,
66
],
[
66,
23,
1114
]
],
[
[
1531,
24,
1093
],
[
1093,
62,
1114
]
],
[
[
1531,
64,
1057
],
[
1057,
23,
1114
]
],
[
[
1531,
24,
259
],
[
259,
23,
1114
]
],
[
[
1531,
25,
980
],
[
980,
23,
1114
]
],
[
[
1531,
25,
1583
],
[
1583,
62,
1114
]
],
[
[
1531,
63,
66
],
[
66,
24,
1093
],
[
1093,
62,
1114
]
],
[
[
1531,
24,
1093
],
[
1093,
63,
66
],
[
66,
23,
1114
]
],
[
[
1531,
64,
1057
],
[
1057,
24,
66
],
[
66,
23,
1114
]
]
] | [
[
[
"Canakinumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
],
[
[
"Canakinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
]
]
] | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate
Canakinumab may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate |
DB00344 | DB00662 | 1,302 | 717 | [
"DDInter1543",
"DDInter1873"
] | Protriptyline | Trimethobenzamide | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. | Moderate | 1 | [
[
[
1302,
24,
717
]
],
[
[
1302,
25,
1425
],
[
1425,
40,
717
]
],
[
[
1302,
21,
29648
],
[
29648,
60,
717
]
],
[
[
1302,
1,
109
],
[
109,
24,
717
]
],
[
[
1302,
24,
1594
],
[
1594,
24,
717
]
],
[
[
1302,
24,
1376
],
[
1376,
63,
717
]
],
[
[
1302,
63,
1242
],
[
1242,
24,
717
]
],
[
[
1302,
40,
413
],
[
413,
63,
717
]
],
[
[
1302,
1,
1405
],
[
1405,
63,
717
]
],
[
[
1302,
40,
1236
],
[
1236,
24,
717
]
]
] | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} (Compound) resembles {v} (Compound)",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Maprotiline"
],
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Protriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
]
] | Protriptyline may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Protriptyline (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Trimethobenzamide (Compound)
Protriptyline (Compound) resembles Duloxetine (Compound) and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Protriptyline (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Protriptyline (Compound) resembles Cyclobenzaprine (Compound) and Cyclobenzaprine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Protriptyline (Compound) resembles Carbamazepine (Compound) and Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide |
DB01232 | DB01261 | 1,327 | 170 | [
"DDInter1640",
"DDInter1679"
] | Saquinavir | Sitagliptin | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due to a relatively benign adverse effect profile as compared to other antiretroviral therapies. While its efficacy was initially limited by exceptionally poor oral bioavailability (approximately 4%), its current indications require the co-administration of ritonavir - a potent enzyme inhibitor - that increases the bioavailability and subsequent serum concentrations of saquinavir, thus dramatically improving antiviral activity.[A214382,L3450,L14351] | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006. | Moderate | 1 | [
[
[
1327,
24,
170
]
],
[
[
1327,
6,
3486
],
[
3486,
45,
170
]
],
[
[
1327,
21,
28850
],
[
28850,
60,
170
]
],
[
[
1327,
24,
52
],
[
52,
62,
170
]
],
[
[
1327,
25,
1616
],
[
1616,
63,
170
]
],
[
[
1327,
63,
1179
],
[
1179,
24,
170
]
],
[
[
1327,
64,
521
],
[
521,
24,
170
]
],
[
[
1327,
62,
222
],
[
222,
24,
170
]
],
[
[
1327,
24,
1254
],
[
1254,
63,
170
]
],
[
[
1327,
1,
915
],
[
915,
24,
170
]
]
] | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
],
[
"Dulaglutide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Saquinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
],
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
]
] | Saquinavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sitagliptin (Compound)
Saquinavir (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagliptin
Saquinavir may lead to a major life threatening interaction when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Saquinavir may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Saquinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin
Saquinavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin |
DB06237 | DB14723 | 438 | 159 | [
"DDInter141",
"DDInter1026"
] | Avanafil | Larotrectinib | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual disturbances associated with off-target PDE6 inhibition. It first received FDA approval on April 27, 2012, with subsequent EMA approval in June 2013. | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
438,
24,
159
]
],
[
[
438,
24,
98
],
[
98,
24,
159
]
],
[
[
438,
25,
1593
],
[
1593,
24,
159
]
],
[
[
438,
63,
1220
],
[
1220,
24,
159
]
],
[
[
438,
64,
1419
],
[
1419,
24,
159
]
],
[
[
438,
24,
129
],
[
129,
25,
159
]
],
[
[
438,
25,
384
],
[
384,
25,
159
]
],
[
[
438,
64,
609
],
[
609,
25,
159
]
],
[
[
438,
24,
98
],
[
98,
63,
222
],
[
222,
23,
159
]
],
[
[
438,
24,
1619
],
[
1619,
62,
222
],
[
222,
23,
159
]
]
] | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
]
] | Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Avanafil may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Avanafil may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Avanafil may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Larotrectinib
Avanafil may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Larotrectinib
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib |
DB01229 | DB05679 | 973 | 1,683 | [
"DDInter1377",
"DDInter1907"
] | Paclitaxel | Ustekinumab | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada. | Moderate | 1 | [
[
[
973,
24,
1683
]
],
[
[
973,
63,
1461
],
[
1461,
23,
1683
]
],
[
[
973,
24,
1362
],
[
1362,
63,
1683
]
],
[
[
973,
63,
33
],
[
33,
24,
1683
]
],
[
[
973,
24,
309
],
[
309,
24,
1683
]
],
[
[
973,
64,
770
],
[
770,
24,
1683
]
],
[
[
973,
25,
908
],
[
908,
64,
1683
]
],
[
[
973,
24,
980
],
[
980,
64,
1683
]
],
[
[
973,
64,
1066
],
[
1066,
25,
1683
]
],
[
[
973,
63,
1461
],
[
1461,
62,
967
],
[
967,
63,
1683
]
]
] | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Antilymphocyte immunoglobulin (horse)"
],
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
]
] | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Paclitaxel may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Ustekinumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may lead to a major life threatening interaction when taken with Ustekinumab
Paclitaxel may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Ustekinumab
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Antilymphocyte immunoglobulin (horse) and Antilymphocyte immunoglobulin (horse) may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab |
DB00467 | DB11348 | 1,467 | 1,065 | [
"DDInter644",
"DDInter279"
] | Enoxacin | Calcium Phosphate | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1467,
24,
1065
]
],
[
[
1467,
40,
1299
],
[
1299,
24,
1065
]
],
[
[
1467,
1,
956
],
[
956,
24,
1065
]
],
[
[
1467,
40,
1299
],
[
1299,
1,
956
],
[
956,
24,
1065
]
],
[
[
1467,
1,
956
],
[
956,
40,
1299
],
[
1299,
24,
1065
]
],
[
[
1467,
40,
739
],
[
739,
40,
1299
],
[
1299,
24,
1065
]
],
[
[
1467,
24,
1606
],
[
1606,
24,
943
],
[
943,
63,
1065
]
],
[
[
1467,
1,
1539
],
[
1539,
1,
945
],
[
945,
24,
1065
]
],
[
[
1467,
24,
1473
],
[
1473,
63,
943
],
[
943,
63,
1065
]
],
[
[
1467,
24,
1606
],
[
1606,
63,
819
],
[
819,
24,
1065
]
]
] | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium gluconate"
],
[
"Magnesium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
]
] | Enoxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin (Compound) resembles Trovafloxacin (Compound) and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium gluconate and Magnesium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate |
DB00987 | DB14811 | 1,224 | 385 | [
"DDInter461",
"DDInter979"
] | Cytarabine (liposomal) | Isatuximab | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma. Along with [daratumumab], another anti-CD38 mAb, isatuximab constitutes a novel treatment modality for patients with difficult-to-treat multiple myeloma. Following three consecutive years on the yearly "Antibodies to watch" list published in "mAb", a peer-reviewed scientific journal dedicated to antibody research,[A38676,A191826,A191829] isatuximab was granted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma.[L12099,L12102] It is manufactured by Sanofi-Aventis U.S. under the brand name Sarclisa. | Moderate | 1 | [
[
[
1224,
24,
385
]
],
[
[
1224,
24,
1362
],
[
1362,
24,
385
]
],
[
[
1224,
63,
377
],
[
377,
24,
385
]
],
[
[
1224,
74,
372
],
[
372,
24,
385
]
],
[
[
1224,
35,
1488
],
[
1488,
24,
385
]
],
[
[
1224,
37,
770
],
[
770,
24,
385
]
],
[
[
1224,
25,
908
],
[
908,
25,
385
]
],
[
[
1224,
64,
581
],
[
581,
25,
385
]
],
[
[
1224,
25,
676
],
[
676,
64,
385
]
],
[
[
1224,
76,
1064
],
[
1064,
25,
385
]
]
] | [
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Cytarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
]
] | Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Cytarabine (Compound) resembles Clofarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Cytarabine (Compound) resembles Fludarabine (Compound) and Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Cytarabine may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Cytarabine may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Isatuximab
Cytarabine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Isatuximab
Cytarabine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Isatuximab
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Cladribine and Cytarabine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Isatuximab |
DB00660 | DB01075 | 1,470 | 1,376 | [
"DDInter1163",
"DDInter569"
] | Metaxalone | Diphenhydramine | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous system depression. Metaxalone is associated with few side effects and is available as a 800 mg scored tablet. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
1470,
24,
1376
]
],
[
[
1470,
24,
649
],
[
649,
63,
1376
]
],
[
[
1470,
63,
128
],
[
128,
24,
1376
]
],
[
[
1470,
24,
832
],
[
832,
24,
1376
]
],
[
[
1470,
21,
28921
],
[
28921,
60,
1376
]
],
[
[
1470,
64,
475
],
[
475,
24,
1376
]
],
[
[
1470,
24,
272
],
[
272,
74,
1376
]
],
[
[
1470,
24,
662
],
[
662,
35,
1376
]
],
[
[
1470,
24,
649
],
[
649,
40,
11
],
[
11,
1,
1376
]
],
[
[
1470,
63,
128
],
[
128,
24,
649
],
[
649,
63,
1376
]
]
] | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
],
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
]
] | Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Metaxalone (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
Metaxalone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Diphenhydramine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Diphenhydramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol (Compound) resembles Toremifene (Compound) and Toremifene (Compound) resembles Diphenhydramine (Compound)
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine |
DB01005 | DB01097 | 995 | 1,377 | [
"DDInter894",
"DDInter1033"
] | Hydroxyurea | Leflunomide | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, hydroxyurea is used sparingly in clinical settings, largely due to lack of knowledge and adherence, the need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
995,
25,
1377
]
],
[
[
995,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
995,
63,
1461
],
[
1461,
23,
1377
]
],
[
[
995,
24,
949
],
[
949,
63,
1377
]
],
[
[
995,
63,
563
],
[
563,
24,
1377
]
],
[
[
995,
63,
1001
],
[
1001,
25,
1377
]
],
[
[
995,
25,
779
],
[
779,
64,
1377
]
],
[
[
995,
24,
1307
],
[
1307,
25,
1377
]
],
[
[
995,
24,
1532
],
[
1532,
64,
1377
]
],
[
[
995,
25,
770
],
[
770,
25,
1377
]
]
] | [
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mechlorethamine"
],
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
],
[
"Melphalan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
]
] | Hydroxyurea (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Leflunomide
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Mechlorethamine and Mechlorethamine may lead to a major life threatening interaction when taken with Leflunomide
Hydroxyurea may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Leflunomide
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Melphalan and Melphalan may lead to a major life threatening interaction when taken with Leflunomide
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Leflunomide
Hydroxyurea may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Leflunomide |
DB00420 | DB06699 | 508 | 774 | [
"DDInter1532",
"DDInter493"
] | Promazine | Degarelix | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
508,
24,
774
]
],
[
[
508,
63,
521
],
[
521,
1,
774
]
],
[
[
508,
23,
112
],
[
112,
23,
774
]
],
[
[
508,
35,
888
],
[
888,
24,
774
]
],
[
[
508,
24,
484
],
[
484,
63,
774
]
],
[
[
508,
24,
455
],
[
455,
24,
774
]
],
[
[
508,
1,
1237
],
[
1237,
24,
774
]
],
[
[
508,
40,
1164
],
[
1164,
24,
774
]
],
[
[
508,
63,
79
],
[
79,
24,
774
]
],
[
[
508,
25,
1487
],
[
1487,
24,
774
]
]
] | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
]
] | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Promazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Degarelix
Promazine (Compound) resembles Tamoxifen (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Promazine (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Promazine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Promazine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix |
DB00231 | DB01069 | 1,174 | 401 | [
"DDInter1761",
"DDInter1533"
] | Temazepam | Promethazine | Temazepam, like many other similar and related benzodiazepines, acts as a gamma-aminobutyric acid (GABA) modulator and is capable of eliciting a variety of actions including sedation, hypnosis, skeletal muscle relaxation, anticonvulsant activity, and anxiolytic action [A175207, A175210, F3718, F3721]. Although the chemical synthesis of temazepam was established by 1965, mainstream contemporary use of the medication did not occur until it's legitimate use as treatment for insomnia was accepted and approved later on. In particular, before temazepam saw regular prescription use in civilians it was - and still is - employed by the US military as a sedative-hypnotic medication to be taken by soldiers, pilots, etc. to obtain the necessary rest required for medical recovery or scheduled maneuvers and operations. Regardless, temazepam has become one of the most frequently prescribed medications internationally and sees | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A190153,A190159,A190150,A190171] Promethazine was granted FDA approval before 29 March 1951.[A190177,L4000] | Moderate | 1 | [
[
[
1174,
24,
401
]
],
[
[
1174,
1,
11275
],
[
11275,
40,
401
]
],
[
[
1174,
24,
1264
],
[
1264,
63,
401
]
],
[
[
1174,
24,
104
],
[
104,
24,
401
]
],
[
[
1174,
6,
7603
],
[
7603,
45,
401
]
],
[
[
1174,
21,
28709
],
[
28709,
60,
401
]
],
[
[
1174,
23,
460
],
[
460,
62,
401
]
],
[
[
1174,
40,
1382
],
[
1382,
24,
401
]
],
[
[
1174,
1,
1563
],
[
1563,
24,
401
]
],
[
[
1174,
25,
475
],
[
475,
24,
401
]
]
] | [
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP2B6"
],
[
"CYP2B6",
"{u} (Gene) is bound by {v} (Compound)",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} (Compound) resembles {v} (Compound)",
"Halazepam"
],
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Temazepam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
]
] | Temazepam (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Promethazine (Compound)
Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Temazepam may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Temazepam (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Promethazine (Compound)
Temazepam (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Promethazine (Compound)
Temazepam may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Promethazine
Temazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Temazepam (Compound) resembles Halazepam (Compound) and Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Temazepam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine |
DB00159 | DB00682 | 940 | 126 | [
"DDInter903",
"DDInter1951"
] | Icosapent | Warfarin | Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Moderate | 1 | [
[
[
940,
24,
126
]
],
[
[
940,
24,
477
],
[
477,
62,
126
]
],
[
[
940,
24,
885
],
[
885,
63,
126
]
],
[
[
940,
24,
1018
],
[
1018,
24,
126
]
],
[
[
940,
63,
942
],
[
942,
25,
126
]
],
[
[
940,
24,
553
],
[
553,
25,
126
]
],
[
[
940,
24,
365
],
[
365,
64,
126
]
],
[
[
940,
24,
1274
],
[
1274,
75,
126
]
],
[
[
940,
24,
477
],
[
477,
63,
1335
],
[
1335,
40,
126
]
],
[
[
940,
24,
885
],
[
885,
6,
6017
],
[
6017,
45,
126
]
]
] | [
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
]
],
[
[
"Icosapent",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Warfarin"
]
]
] | Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Warfarin (Compound) and Flurbiprofen may lead to a major life threatening interaction when taken with Warfarin
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Warfarin (Compound)
Icosapent may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Warfarin (Compound) |
DB01030 | DB01229 | 869 | 973 | [
"DDInter1835",
"DDInter1377"
] | Topotecan | Paclitaxel | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Moderate | 1 | [
[
[
869,
24,
973
]
],
[
[
869,
24,
310
],
[
310,
63,
973
]
],
[
[
869,
5,
11582
],
[
11582,
44,
973
]
],
[
[
869,
6,
8374
],
[
8374,
45,
973
]
],
[
[
869,
7,
14544
],
[
14544,
45,
973
]
],
[
[
869,
18,
7824
],
[
7824,
46,
973
]
],
[
[
869,
7,
2903
],
[
2903,
46,
973
]
],
[
[
869,
7,
8839
],
[
8839,
57,
973
]
],
[
[
869,
18,
9531
],
[
9531,
57,
973
]
],
[
[
869,
21,
29267
],
[
29267,
60,
973
]
]
] | [
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) treats {v} (Disease)",
"lung cancer"
],
[
"lung cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"ABCC10"
],
[
"ABCC10",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDCA8"
],
[
"CDCA8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"MMP1"
],
[
"MMP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"GNPDA1"
],
[
"GNPDA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"FOXJ3"
],
[
"FOXJ3",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Alanine aminotransferase increased"
],
[
"Alanine aminotransferase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
]
] | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Topotecan (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Paclitaxel (Compound)
Topotecan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Paclitaxel (Compound)
Topotecan (Compound) upregulates ABCC10 (Gene) and ABCC10 (Gene) is bound by Paclitaxel (Compound)
Topotecan (Compound) downregulates CDCA8 (Gene) and CDCA8 (Gene) is upregulated by Paclitaxel (Compound)
Topotecan (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Paclitaxel (Compound)
Topotecan (Compound) upregulates GNPDA1 (Gene) and GNPDA1 (Gene) is downregulated by Paclitaxel (Compound)
Topotecan (Compound) downregulates FOXJ3 (Gene) and FOXJ3 (Gene) is downregulated by Paclitaxel (Compound)
Topotecan (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Paclitaxel (Compound) |
DB01024 | DB01331 | 1,096 | 1,558 | [
"DDInter1252",
"DDInter325"
] | Mycophenolic acid | Cefoxitin | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic | Cefoxitin is a semi-synthetic, broad-spectrum cepha antibiotic for intravenous administration. It is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>. | Moderate | 1 | [
[
[
1096,
24,
1558
]
],
[
[
1096,
24,
665
],
[
665,
40,
1558
]
],
[
[
1096,
24,
1402
],
[
1402,
1,
1558
]
],
[
[
1096,
63,
277
],
[
277,
1,
1558
]
],
[
[
1096,
63,
164
],
[
164,
40,
1558
]
],
[
[
1096,
21,
28775
],
[
28775,
60,
1558
]
],
[
[
1096,
24,
1448
],
[
1448,
24,
1558
]
],
[
[
1096,
63,
1132
],
[
1132,
24,
1558
]
],
[
[
1096,
24,
665
],
[
665,
40,
11239
],
[
11239,
1,
1558
]
],
[
[
1096,
63,
277
],
[
277,
1,
1402
],
[
1402,
1,
1558
]
]
] | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefotetan"
],
[
"Cefotetan",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefalotin"
],
[
"Cefalotin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Phlebitis"
],
[
"Phlebitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gentamicin"
],
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefuroxime"
],
[
"Cefuroxime",
"{u} (Compound) resembles {v} (Compound)",
"Cephaloglycin"
],
[
"Cephaloglycin",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
],
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefmetazole"
],
[
"Cefmetazole",
"{u} (Compound) resembles {v} (Compound)",
"Cefotetan"
],
[
"Cefotetan",
"{u} (Compound) resembles {v} (Compound)",
"Cefoxitin"
]
]
] | Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cefoxitin (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefotetan and Cefotetan (Compound) resembles Cefoxitin (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefoxitin (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefalotin and Cefalotin (Compound) resembles Cefoxitin (Compound)
Mycophenolic acid (Compound) causes Phlebitis (Side Effect) and Phlebitis (Side Effect) is caused by Cefoxitin (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Gentamicin and Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefoxitin
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefuroxime and Cefuroxime (Compound) resembles Cephaloglycin (Compound) and Cephaloglycin (Compound) resembles Cefoxitin (Compound)
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Cefmetazole and Cefmetazole (Compound) resembles Cefotetan (Compound) and Cefotetan (Compound) resembles Cefoxitin (Compound) |
DB00258 | DB00884 | 666 | 1,008 | [
"DDInter270",
"DDInter1604"
] | Calcium acetate | Risedronic acid | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label]. | Moderate | 1 | [
[
[
666,
24,
1008
]
],
[
[
666,
24,
1485
],
[
1485,
1,
1008
]
],
[
[
666,
5,
11639
],
[
11639,
44,
1008
]
],
[
[
666,
21,
28898
],
[
28898,
60,
1008
]
],
[
[
666,
24,
1485
],
[
1485,
40,
715
],
[
715,
1,
1008
]
],
[
[
666,
5,
11639
],
[
11639,
44,
1485
],
[
1485,
1,
1008
]
],
[
[
666,
21,
28898
],
[
28898,
60,
1485
],
[
1485,
1,
1008
]
],
[
[
666,
40,
11360
],
[
11360,
21,
28719
],
[
28719,
60,
1008
]
],
[
[
666,
24,
1485
],
[
1485,
1,
11549
],
[
11549,
1,
1008
]
],
[
[
666,
10,
11645
],
[
11645,
9,
7720
],
[
7720,
45,
1008
]
]
] | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) treats {v} (Disease)",
"osteoporosis"
],
[
"osteoporosis",
"{u} (Disease) is treated by {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Etidronic acid"
],
[
"Etidronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) treats {v} (Disease)",
"osteoporosis"
],
[
"osteoporosis",
"{u} (Disease) is treated by {v} (Compound)",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) resembles {v} (Compound)",
"Acetic acid"
],
[
"Acetic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alendronic acid"
],
[
"Alendronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Histamine Phosphate"
],
[
"Histamine Phosphate",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium acetate",
"{u} (Compound) palliates {v} (Disease)",
"chronic kidney failure"
],
[
"chronic kidney failure",
"{u} (Disease) is associated with {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Risedronic acid"
]
]
] | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Alendronic acid and Alendronic acid (Compound) resembles Risedronic acid (Compound)
Calcium acetate (Compound) treats osteoporosis (Disease) and osteoporosis (Disease) is treated by Risedronic acid (Compound)
Calcium acetate (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Risedronic acid (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Alendronic acid and Alendronic acid (Compound) resembles Etidronic acid (Compound) and Etidronic acid (Compound) resembles Risedronic acid (Compound)
Calcium acetate (Compound) treats osteoporosis (Disease) and osteoporosis (Disease) is treated by Alendronic acid (Compound) and Alendronic acid (Compound) resembles Risedronic acid (Compound)
Calcium acetate (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Alendronic acid (Compound) and Alendronic acid (Compound) resembles Risedronic acid (Compound)
Calcium acetate (Compound) resembles Acetic acid (Compound) and Acetic acid (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Risedronic acid (Compound)
Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Alendronic acid and Alendronic acid (Compound) resembles Histamine Phosphate (Compound) and Histamine Phosphate (Compound) resembles Risedronic acid (Compound)
Calcium acetate (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is associated with PTGS2 (Gene) and PTGS2 (Gene) is bound by Risedronic acid (Compound) |
DB00188 | DB10989 | 168 | 496 | [
"DDInter222",
"DDInter858"
] | Bortezomib | Hepatitis A Vaccine | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Moderate | 1 | [
[
[
168,
24,
496
]
],
[
[
168,
24,
4
],
[
4,
24,
496
]
],
[
[
168,
24,
738
],
[
738,
63,
496
]
],
[
[
168,
23,
1101
],
[
1101,
24,
496
]
],
[
[
168,
25,
976
],
[
976,
24,
496
]
],
[
[
168,
63,
1560
],
[
1560,
24,
496
]
],
[
[
168,
64,
1066
],
[
1066,
24,
496
]
],
[
[
168,
23,
1476
],
[
1476,
63,
496
]
],
[
[
168,
25,
676
],
[
676,
63,
496
]
],
[
[
168,
24,
4
],
[
4,
24,
1093
],
[
1093,
63,
496
]
]
] | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
]
] | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may cause a minor interaction that can limit clinical effects when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine |
DB00960 | DB01075 | 887 | 1,376 | [
"DDInter1471",
"DDInter569"
] | Pindolol | Diphenhydramine | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s. Pindolol was granted FDA approval on 3 September 1982. | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for "night time" use [L5263, L5281, L5287]. Diphenhydramine is also used in combination with as the anti-nausea drug where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system . Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid . As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties. | Moderate | 1 | [
[
[
887,
24,
1376
]
],
[
[
887,
24,
401
],
[
401,
24,
1376
]
],
[
[
887,
6,
12523
],
[
12523,
45,
1376
]
],
[
[
887,
21,
28921
],
[
28921,
60,
1376
]
],
[
[
887,
63,
530
],
[
530,
24,
1376
]
],
[
[
887,
24,
1053
],
[
1053,
63,
1376
]
],
[
[
887,
40,
1121
],
[
1121,
24,
1376
]
],
[
[
887,
1,
699
],
[
699,
63,
1376
]
],
[
[
887,
1,
88
],
[
88,
24,
1376
]
],
[
[
887,
24,
820
],
[
820,
74,
1376
]
]
] | [
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Bisoprolol"
],
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Pindolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
]
] | Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pindolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Diphenhydramine (Compound)
Pindolol (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Diphenhydramine (Compound)
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pindolol (Compound) resembles Bisoprolol (Compound) and Bisoprolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pindolol (Compound) resembles Nadolol (Compound) and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pindolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine
Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Diphenhydramine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine |
DB00741 | DB09237 | 167 | 1,586 | [
"DDInter885",
"DDInter1045"
] | Hydrocortisone | Levamlodipine | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity. Levamlodipine was granted FDA approval on 19 December 2019. | Moderate | 1 | [
[
[
167,
24,
1586
]
],
[
[
167,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
167,
24,
549
],
[
549,
24,
1586
]
],
[
[
167,
40,
870
],
[
870,
24,
1586
]
],
[
[
167,
1,
1486
],
[
1486,
24,
1586
]
],
[
[
167,
25,
593
],
[
593,
24,
1586
]
],
[
[
167,
24,
159
],
[
159,
63,
1586
]
],
[
[
167,
64,
1057
],
[
1057,
24,
1586
]
],
[
[
167,
24,
129
],
[
129,
25,
1586
]
],
[
[
167,
24,
913
],
[
913,
64,
1586
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamlodipine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levamlodipine"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Levamlodipine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Levamlodipine |
DB00048 | DB01017 | 1,595 | 1,669 | [
"DDInter435",
"DDInter1224"
] | Collagenase clostridium histolyticum | Minocycline | Collagenase clostridium histolyticum is an enzyme produced by the bacterium Clostridium histolyticum. It is beneficial in the breakdown of collagen plaques for the treatment of Dupuytren's contracture and Peyronie's disease. The topical formulation is used for the debridement of necrotic tissue due to burns or chronic ulcers. On July 6, 2020 a combination of injectable bacterial collagenases was approved by the FDA for the treatment of cellulite in adult women. Also known as Qwo, this injection is the first approved injectable treatment for cellulite and was developed by Endo International. | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines. Minocycline was granted FDA approval on 30 June 1971. | Moderate | 1 | [
[
[
1595,
24,
1669
]
],
[
[
1595,
24,
1572
],
[
1572,
1,
1669
]
],
[
[
1595,
24,
1545
],
[
1545,
40,
1669
]
],
[
[
1595,
24,
279
],
[
279,
63,
1669
]
],
[
[
1595,
24,
126
],
[
126,
24,
1669
]
],
[
[
1595,
24,
1572
],
[
1572,
40,
964
],
[
964,
1,
1669
]
],
[
[
1595,
24,
964
],
[
964,
1,
1572
],
[
1572,
1,
1669
]
],
[
[
1595,
24,
279
],
[
279,
63,
1572
],
[
1572,
1,
1669
]
],
[
[
1595,
24,
885
],
[
885,
62,
1252
],
[
1252,
24,
1669
]
],
[
[
1595,
24,
235
],
[
235,
63,
266
],
[
266,
63,
1669
]
]
] | [
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxytetracycline"
],
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
],
[
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desirudin"
],
[
"Desirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
],
[
"Bismuth subsalicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
]
]
] | Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Oxytetracycline and Oxytetracycline (Compound) resembles Minocycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Doxycycline (Compound) and Doxycycline (Compound) resembles Minocycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Minocycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Minocycline (Compound)
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Minocycline
Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Desirudin and Desirudin may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate and Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Minocycline |
DB00553 | DB00777 | 92 | 146 | [
"DDInter1177",
"DDInter1537"
] | Methoxsalen | Propiomazine | A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation. | Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment of obsessive-compulsive disorder and severe behavioral disorders in autism. Structurally and pharmacologically similar to clozapine, propiomazine binds to alpha(1), dopamine, histamine H1, muscarinic, and serotonin type 2 (5-HT2) receptors. | Moderate | 1 | [
[
[
92,
24,
146
]
],
[
[
92,
63,
508
],
[
508,
1,
146
]
],
[
[
92,
24,
401
],
[
401,
63,
146
]
],
[
[
92,
24,
1178
],
[
1178,
1,
146
]
],
[
[
92,
24,
104
],
[
104,
40,
146
]
],
[
[
92,
63,
245
],
[
245,
24,
146
]
],
[
[
92,
24,
1419
],
[
1419,
24,
146
]
],
[
[
92,
63,
508
],
[
508,
35,
401
],
[
401,
63,
146
]
],
[
[
92,
24,
401
],
[
401,
74,
508
],
[
508,
1,
146
]
],
[
[
92,
24,
1178
],
[
1178,
1,
508
],
[
508,
1,
146
]
]
] | [
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
],
[
[
"Methoxsalen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Propiomazine"
]
]
] | Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Propiomazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Propiomazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Promethazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) resembles Promazine (Compound) and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Propiomazine (Compound)
Methoxsalen may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Promazine (Compound) and Promazine (Compound) resembles Propiomazine (Compound) |
DB00687 | DB11642 | 870 | 938 | [
"DDInter747",
"DDInter1480"
] | Fludrocortisone | Pitolisant | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as increasing the signalling of other neurotransmitters in the brain. In a European clinical trial of adult patients with narcolepsy, there was a reduction in the Epworth Sleepiness Scale (ESS) score from pitolisant therapy compared to placebo. The therapeutic effectiveness of pitolisant was comparable to that of [modafinil]. Pitolisant therapy was also effective in treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and increased the mean sleep onset latency. Adolescent patients with cataplexy also experienced a slight improvement in the frequency and severity of symptoms ; however, the safety of use in adolescent or paediatric patients have not been established with pitolisant. Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 for the treatment of narcolepsy with or without cataplexy. FDA approved the use of pitolisant in 2019 for excessive daytime sleepiness (EDS) associated with narcolepsy in adults. | Moderate | 1 | [
[
[
870,
24,
938
]
],
[
[
870,
24,
760
],
[
760,
24,
938
]
],
[
[
870,
63,
600
],
[
600,
24,
938
]
],
[
[
870,
62,
1018
],
[
1018,
24,
938
]
],
[
[
870,
23,
1674
],
[
1674,
24,
938
]
],
[
[
870,
1,
891
],
[
891,
24,
938
]
],
[
[
870,
24,
283
],
[
283,
63,
938
]
],
[
[
870,
25,
676
],
[
676,
63,
938
]
],
[
[
870,
24,
351
],
[
351,
64,
938
]
],
[
[
870,
25,
57
],
[
57,
25,
938
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pitolisant"
]
]
] | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Pitolisant
Fludrocortisone may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Pitolisant |
DB06650 | DB08880 | 1,500 | 1,510 | [
"DDInter1324",
"DDInter1771"
] | Ofatumumab | Teriflunomide | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD- | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Major | 2 | [
[
[
1500,
25,
1510
]
],
[
[
1500,
24,
221
],
[
221,
63,
1510
]
],
[
[
1500,
63,
1136
],
[
1136,
24,
1510
]
],
[
[
1500,
24,
1430
],
[
1430,
24,
1510
]
],
[
[
1500,
24,
713
],
[
713,
64,
1510
]
],
[
[
1500,
64,
1066
],
[
1066,
25,
1510
]
],
[
[
1500,
63,
1184
],
[
1184,
25,
1510
]
],
[
[
1500,
25,
908
],
[
908,
25,
1510
]
],
[
[
1500,
25,
375
],
[
375,
64,
1510
]
],
[
[
1500,
24,
221
],
[
221,
63,
36
],
[
36,
25,
1510
]
]
] | [
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
],
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Ofatumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
],
[
"Poliovirus type 1 antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
]
] | Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Teriflunomide
Ofatumumab may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated) and Poliovirus type 1 antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Teriflunomide |
DB00289 | DB00836 | 847 | 543 | [
"DDInter132",
"DDInter1088"
] | Atomoxetine | Loperamide | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxylate] and [haloperidol]. Due to pharmacological properties, loperamide has been misused and abused to self-manage opioid withdrawal symptoms and to induce euphoria.[A251610, A251625] However, loperamide is associated with a risk for experiencing a range of adverse effects, often life-threatening, if taking for non-therapeutic reasons or at doses higher than the recommended dose. | Moderate | 1 | [
[
[
847,
24,
543
]
],
[
[
847,
40,
649
],
[
649,
1,
543
]
],
[
[
847,
24,
888
],
[
888,
24,
543
]
],
[
[
847,
6,
8374
],
[
8374,
45,
543
]
],
[
[
847,
21,
28722
],
[
28722,
60,
543
]
],
[
[
847,
25,
982
],
[
982,
63,
543
]
],
[
[
847,
24,
688
],
[
688,
63,
543
]
],
[
[
847,
63,
600
],
[
600,
24,
543
]
],
[
[
847,
1,
413
],
[
413,
63,
543
]
],
[
[
847,
1,
1594
],
[
1594,
24,
543
]
]
] | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} (Compound) resembles {v} (Compound)",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Maprotiline"
],
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
]
]
] | Atomoxetine (Compound) resembles Clofedanol (Compound) and Clofedanol (Compound) resembles Loperamide (Compound)
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Atomoxetine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Loperamide (Compound)
Atomoxetine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Loperamide (Compound)
Atomoxetine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Atomoxetine (Compound) resembles Maprotiline (Compound) and Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Loperamide
Atomoxetine (Compound) resembles Doxylamine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide |
DB00561 | DB09080 | 1,048 | 144 | [
"DDInter591",
"DDInter1331"
] | Doxapram | Olodaterol | A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225) | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated symptoms such as shortness of breath, cough, and sputum production. Single doses of olodaterol have been shown to improve forced expiratory volume in 1 sec (FEV1) for 24 h in patients with COPD, allowing once daily dosing. A once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period. Despite similarities in symptoms, olodaterol is not indicated for the treatment of acute exacerbations of COPD or for the treatment of asthma. | Moderate | 1 | [
[
[
1048,
24,
144
]
],
[
[
1048,
64,
534
],
[
534,
24,
144
]
],
[
[
1048,
40,
543
],
[
543,
24,
144
]
],
[
[
1048,
24,
1445
],
[
1445,
24,
144
]
],
[
[
1048,
63,
1290
],
[
1290,
24,
144
]
],
[
[
1048,
25,
453
],
[
453,
24,
144
]
],
[
[
1048,
24,
1032
],
[
1032,
63,
144
]
],
[
[
1048,
25,
1629
],
[
1629,
63,
144
]
],
[
[
1048,
25,
290
],
[
290,
25,
144
]
],
[
[
1048,
64,
534
],
[
534,
25,
1011
],
[
1011,
24,
144
]
]
] | [
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} (Compound) resembles {v} (Compound)",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midodrine"
],
[
"Midodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linezolid"
],
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olodaterol"
]
],
[
[
"Doxapram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
]
] | Doxapram may lead to a major life threatening interaction when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram (Compound) resembles Loperamide (Compound) and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Midodrine and Midodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram may lead to a major life threatening interaction when taken with Linezolid and Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Doxapram may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Olodaterol
Doxapram may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol |
DB00618 | DB00855 | 1,572 | 213 | [
"DDInter498",
"DDInter72"
] | Demeclocycline | Aminolevulinic acid | A tetracycline analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time. | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Major | 2 | [
[
[
1572,
25,
213
]
],
[
[
1572,
23,
1577
],
[
1577,
25,
213
]
],
[
[
1572,
23,
504
],
[
504,
64,
213
]
],
[
[
1572,
62,
1028
],
[
1028,
25,
213
]
],
[
[
1572,
63,
92
],
[
92,
25,
213
]
],
[
[
1572,
40,
1620
],
[
1620,
25,
213
]
],
[
[
1572,
1,
753
],
[
753,
25,
213
]
],
[
[
1572,
25,
1517
],
[
1517,
64,
213
]
],
[
[
1572,
1,
1669
],
[
1669,
64,
213
]
],
[
[
1572,
64,
640
],
[
640,
25,
213
]
]
] | [
[
[
"Demeclocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methoxsalen"
],
[
"Methoxsalen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
],
[
"Tetracycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tigecycline"
],
[
"Tigecycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Minocycline"
],
[
"Minocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
],
[
[
"Demeclocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aminolevulinic acid"
]
]
] | Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide and Hydroflumethiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide and Hydrochlorothiazide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline may cause a minor interaction that can limit clinical effects when taken with Torasemide and Torasemide may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Methoxsalen and Methoxsalen may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline (Compound) resembles Tetracycline (Compound) and Tetracycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline (Compound) resembles Tigecycline (Compound) and Tigecycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline (Compound) resembles Minocycline (Compound) and Minocycline may lead to a major life threatening interaction when taken with Aminolevulinic acid
Demeclocycline may lead to a major life threatening interaction when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Aminolevulinic acid |
DB08820 | DB11691 | 1,478 | 1,499 | [
"DDInter997",
"DDInter1258"
] | Ivacaftor | Naldemedine | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Moderate | 1 | [
[
[
1478,
24,
1499
]
],
[
[
1478,
62,
307
],
[
307,
23,
1499
]
],
[
[
1478,
63,
932
],
[
932,
24,
1499
]
],
[
[
1478,
64,
723
],
[
723,
24,
1499
]
],
[
[
1478,
24,
1670
],
[
1670,
24,
1499
]
],
[
[
1478,
25,
1339
],
[
1339,
63,
1499
]
],
[
[
1478,
24,
1654
],
[
1654,
63,
1499
]
],
[
[
1478,
25,
1593
],
[
1593,
24,
1499
]
],
[
[
1478,
23,
1135
],
[
1135,
24,
1499
]
],
[
[
1478,
64,
697
],
[
697,
25,
1499
]
]
] | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
],
[
"Somapacitan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Ivacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
]
] | Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan and Somapacitan may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Ivacaftor may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may lead to a major life threatening interaction when taken with Naldemedine |
DB00387 | DB00388 | 1,386 | 1,636 | [
"DDInter1528",
"DDInter1453"
] | Procyclidine | Phenylephrine | A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Moderate | 1 | [
[
[
1386,
24,
1636
]
],
[
[
1386,
24,
61
],
[
61,
40,
1636
]
],
[
[
1386,
35,
1192
],
[
1192,
63,
1636
]
],
[
[
1386,
24,
1123
],
[
1123,
63,
1636
]
],
[
[
1386,
40,
1105
],
[
1105,
24,
1636
]
],
[
[
1386,
40,
456
],
[
456,
63,
1636
]
],
[
[
1386,
24,
1264
],
[
1264,
64,
1636
]
],
[
[
1386,
24,
61
],
[
61,
40,
1357
],
[
1357,
1,
1636
]
],
[
[
1386,
35,
1192
],
[
1192,
24,
61
],
[
61,
40,
1636
]
],
[
[
1386,
24,
1123
],
[
1123,
24,
61
],
[
61,
40,
1636
]
]
] | [
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} (Compound) resembles {v} (Compound)",
"Metaraminol"
],
[
"Metaraminol",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
]
],
[
[
"Procyclidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
]
]
] | Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium (Compound) resembles Phenylephrine (Compound)
Procyclidine (Compound) resembles Glycopyrronium (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Procyclidine (Compound) resembles Trihexyphenidyl (Compound) and Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Procyclidine (Compound) resembles Biperiden (Compound) and Biperiden may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Phenylephrine
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium (Compound) resembles Metaraminol (Compound) and Metaraminol (Compound) resembles Phenylephrine (Compound)
Procyclidine (Compound) resembles Glycopyrronium (Compound) and Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium (Compound) resembles Phenylephrine (Compound)
Procyclidine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium (Compound) resembles Phenylephrine (Compound) |
DB00013 | DB00945 | 1,255 | 1,479 | [
"DDInter1905",
"DDInter20"
] | Urokinase | Acetylsalicylic acid | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others . Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label]. | Moderate | 1 | [
[
[
1255,
24,
1479
]
],
[
[
1255,
24,
1338
],
[
1338,
24,
1479
]
],
[
[
1255,
23,
297
],
[
297,
62,
1479
]
],
[
[
1255,
24,
557
],
[
557,
63,
1479
]
],
[
[
1255,
64,
1578
],
[
1578,
24,
1479
]
],
[
[
1255,
25,
1226
],
[
1226,
24,
1479
]
],
[
[
1255,
25,
256
],
[
256,
63,
1479
]
],
[
[
1255,
25,
1046
],
[
1046,
64,
1479
]
],
[
[
1255,
25,
1172
],
[
1172,
25,
1479
]
],
[
[
1255,
24,
886
],
[
886,
25,
1479
]
]
] | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
],
[
"Meclofenamic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clove",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tirofiban"
],
[
"Tirofiban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
"Ketorolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acetylsalicylic acid"
]
]
] | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Urokinase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Urokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Urokinase may lead to a major life threatening interaction when taken with Tirofiban and Tirofiban may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Urokinase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid
Urokinase may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Urokinase may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Acetylsalicylic acid
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac may lead to a major life threatening interaction when taken with Acetylsalicylic acid |
DB00496 | DB01211 | 194 | 609 | [
"DDInter480",
"DDInter393"
] | Darifenacin | Clarithromycin | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarithromycin may be bacteriostatic or bactericidal depending on the organism and drug concentration. | Moderate | 1 | [
[
[
194,
24,
609
]
],
[
[
194,
6,
8374
],
[
8374,
45,
609
]
],
[
[
194,
18,
9429
],
[
9429,
57,
609
]
],
[
[
194,
21,
28779
],
[
28779,
60,
609
]
],
[
[
194,
63,
600
],
[
600,
23,
609
]
],
[
[
194,
24,
752
],
[
752,
23,
609
]
],
[
[
194,
40,
1413
],
[
1413,
23,
609
]
],
[
[
194,
24,
913
],
[
913,
63,
609
]
],
[
[
194,
63,
883
],
[
883,
24,
609
]
],
[
[
194,
25,
760
],
[
760,
63,
609
]
]
] | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} (Compound) downregulates {v} (Gene)",
"CNDP2"
],
[
"CNDP2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Darifenacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
]
] | Darifenacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Darifenacin (Compound) downregulates CNDP2 (Gene) and CNDP2 (Gene) is downregulated by Clarithromycin (Compound)
Darifenacin (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Clarithromycin (Compound)
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Darifenacin (Compound) resembles Fexofenadine (Compound) and Fexofenadine may cause a minor interaction that can limit clinical effects when taken with Clarithromycin
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Darifenacin may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin |
DB01406 | DB11978 | 984 | 124 | [
"DDInter472",
"DDInter822"
] | Danazol | Glasdegib | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionality. The great lipophilicity of this group of compounds brought interest to further modification. This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed. Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). Glasdegib targets cancerous cells by inhibiting the sonic hedgehog receptor smoothened (SMO), a transmembrane protein involved in the Hedgehog (Hh) signaling cascade. Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.[A258498,A258503] Although the efficacy of glasdegib monotherapy is limited, the landmark Phase 2 Bright AML 1003 trial showed a superior overall survival and complete response when glasdegib is combined with low dose cytarabine. Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due to glasdegib's more favorable side effects profile. | Moderate | 1 | [
[
[
984,
24,
124
]
],
[
[
984,
25,
1135
],
[
1135,
23,
124
]
],
[
[
984,
63,
629
],
[
629,
24,
124
]
],
[
[
984,
24,
159
],
[
159,
63,
124
]
],
[
[
984,
24,
1670
],
[
1670,
24,
124
]
],
[
[
984,
25,
1510
],
[
1510,
24,
124
]
],
[
[
984,
63,
11
],
[
11,
25,
124
]
],
[
[
984,
24,
985
],
[
985,
25,
124
]
],
[
[
984,
64,
1425
],
[
1425,
25,
124
]
],
[
[
984,
24,
1017
],
[
1017,
64,
124
]
]
] | [
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
],
[
[
"Danazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Glasdegib"
]
]
] | Danazol may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Danazol may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Glasdegib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Glasdegib
Danazol may lead to a major life threatening interaction when taken with Cisapride and Cisapride may lead to a major life threatening interaction when taken with Glasdegib
Danazol may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Glasdegib |
DB01611 | DB09276 | 1,487 | 381 | [
"DDInter893",
"DDInter1682"
] | Hydroxychloroquine | Sodium aurothiomalate | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no value in the presence of extensive deformities or in the treatment of other forms of arthritis. | Major | 2 | [
[
[
1487,
25,
381
]
],
[
[
1487,
63,
491
],
[
491,
24,
381
]
],
[
[
1487,
24,
1047
],
[
1047,
24,
381
]
],
[
[
1487,
25,
1593
],
[
1593,
24,
381
]
],
[
[
1487,
24,
1480
],
[
1480,
63,
381
]
],
[
[
1487,
64,
1555
],
[
1555,
24,
381
]
],
[
[
1487,
64,
1377
],
[
1377,
25,
381
]
],
[
[
1487,
25,
1292
],
[
1292,
25,
381
]
],
[
[
1487,
63,
491
],
[
491,
24,
1683
],
[
1683,
24,
381
]
],
[
[
1487,
24,
1047
],
[
1047,
63,
491
],
[
491,
24,
381
]
]
] | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
]
] | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Hydroxychloroquine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Hydroxychloroquine may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Hydroxychloroquine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Sodium aurothiomalate
Hydroxychloroquine may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Sodium aurothiomalate
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate |
DB00526 | DB00539 | 1,555 | 11 | [
"DDInter1355",
"DDInter1837"
] | Oxaliplatin | Toremifene | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Major | 2 | [
[
[
1555,
25,
11
]
],
[
[
1555,
6,
7950
],
[
7950,
45,
11
]
],
[
[
1555,
23,
1247
],
[
1247,
62,
11
]
],
[
[
1555,
24,
112
],
[
112,
62,
11
]
],
[
[
1555,
63,
62
],
[
62,
24,
11
]
],
[
[
1555,
24,
144
],
[
144,
63,
11
]
],
[
[
1555,
24,
1250
],
[
1250,
64,
11
]
],
[
[
1555,
25,
985
],
[
985,
64,
11
]
],
[
[
1555,
63,
1302
],
[
1302,
25,
11
]
],
[
[
1555,
64,
17
],
[
17,
25,
11
]
]
] | [
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
],
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protriptyline"
],
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
]
]
] | Oxaliplatin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Toremifene (Compound)
Oxaliplatin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Toremifene
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Tacrine and Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Toremifene
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may lead to a major life threatening interaction when taken with Toremifene
Oxaliplatin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Toremifene
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Protriptyline and Protriptyline may lead to a major life threatening interaction when taken with Toremifene
Oxaliplatin may lead to a major life threatening interaction when taken with Sotalol and Sotalol may lead to a major life threatening interaction when taken with Toremifene |
DB00687 | DB09065 | 870 | 760 | [
"DDInter747",
"DDInter424"
] | Fludrocortisone | Cobicistat | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered agents that are metabolized by CYP3A enzymes. More specifically, cobicistat is indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection. Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile. | Moderate | 1 | [
[
[
870,
24,
760
]
],
[
[
870,
63,
1101
],
[
1101,
23,
760
]
],
[
[
870,
24,
555
],
[
555,
23,
760
]
],
[
[
870,
24,
938
],
[
938,
63,
760
]
],
[
[
870,
24,
875
],
[
875,
24,
760
]
],
[
[
870,
63,
723
],
[
723,
24,
760
]
],
[
[
870,
1,
167
],
[
167,
24,
760
]
],
[
[
870,
23,
659
],
[
659,
63,
760
]
],
[
[
870,
64,
78
],
[
78,
24,
760
]
],
[
[
870,
23,
307
],
[
307,
24,
760
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
],
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
]
] | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant and Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fludrocortisone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fludrocortisone may lead to a major life threatening interaction when taken with Droperidol and Droperidol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat |
DB00816 | DB06699 | 1,674 | 774 | [
"DDInter1346",
"DDInter493"
] | Orciprenaline | Degarelix | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008. | Moderate | 1 | [
[
[
1674,
24,
774
]
],
[
[
1674,
63,
521
],
[
521,
1,
774
]
],
[
[
1674,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1674,
63,
888
],
[
888,
24,
774
]
],
[
[
1674,
24,
956
],
[
956,
24,
774
]
],
[
[
1674,
24,
484
],
[
484,
63,
774
]
],
[
[
1674,
35,
1148
],
[
1148,
24,
774
]
],
[
[
1674,
25,
33
],
[
33,
25,
774
]
],
[
[
1674,
24,
880
],
[
880,
64,
774
]
],
[
[
1674,
64,
1176
],
[
1176,
25,
774
]
]
] | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} (Compound) causes {v} (Side Effect)",
"Urticaria"
],
[
"Urticaria",
"{u} (Side Effect) is caused by {v} (Compound)",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
],
[
[
"Orciprenaline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Degarelix"
]
]
] | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Orciprenaline (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Orciprenaline (Compound) resembles Isoprenaline (Compound) and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Orciprenaline may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may lead to a major life threatening interaction when taken with Degarelix
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine and Ivabradine may lead to a major life threatening interaction when taken with Degarelix
Orciprenaline may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may lead to a major life threatening interaction when taken with Degarelix |
DB00912 | DB01583 | 473 | 624 | [
"DDInter1581",
"DDInter1075"
] | Repaglinide | Liotrix | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion. It is now known that the thyroid gland secretes approximately ten times more T4 than T3 and that 80% of serum T3 is derived from deiodination of T4 in peripheral tissues. Administration of levothyroxine alone is sufficient for maintaining serum T4 and T3 levels in most patients and combination hormone replacement therapy generally offers no therapeutic advantage. In fact, administration of T3 may result in supratherapeutic levels of T3. | Moderate | 1 | [
[
[
473,
24,
624
]
],
[
[
473,
63,
1152
],
[
1152,
1,
624
]
],
[
[
473,
63,
542
],
[
542,
40,
624
]
],
[
[
473,
6,
15333
],
[
15333,
45,
624
]
],
[
[
473,
21,
28898
],
[
28898,
60,
624
]
],
[
[
473,
63,
417
],
[
417,
23,
624
]
],
[
[
473,
24,
135
],
[
135,
63,
624
]
],
[
[
473,
63,
1026
],
[
1026,
24,
624
]
],
[
[
473,
24,
123
],
[
123,
24,
624
]
],
[
[
473,
63,
1152
],
[
1152,
1,
542
],
[
542,
40,
624
]
]
] | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
],
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
],
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} (Compound) resembles {v} (Compound)",
"Liotrix"
]
]
] | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Compound)
Repaglinide (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Liotrix (Compound)
Repaglinide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Liotrix (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Liotrix
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Liotrix
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Levothyroxine (Compound) and Levothyroxine (Compound) resembles Liotrix (Compound) |
DB00407 | DB00682 | 202 | 126 | [
"DDInter115",
"DDInter1951"
] | Ardeparin | Warfarin | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with an average molecular weight of 5500 to 6500. Normiflo was withdrawn from the US market in March 2000. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Major | 2 | [
[
[
202,
25,
126
]
],
[
[
202,
25,
477
],
[
477,
62,
126
]
],
[
[
202,
24,
557
],
[
557,
63,
126
]
],
[
[
202,
25,
885
],
[
885,
63,
126
]
],
[
[
202,
64,
1018
],
[
1018,
24,
126
]
],
[
[
202,
24,
121
],
[
121,
24,
126
]
],
[
[
202,
63,
1595
],
[
1595,
24,
126
]
],
[
[
202,
25,
405
],
[
405,
64,
126
]
],
[
[
202,
64,
942
],
[
942,
25,
126
]
],
[
[
202,
36,
553
],
[
553,
25,
126
]
]
] | [
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deoxycholic acid"
],
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Collagenase clostridium histolyticum"
],
[
"Collagenase clostridium histolyticum",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Ardeparin",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
]
] | Ardeparin may lead to a major life threatening interaction when taken with Cilostazol and Cilostazol may cause a minor interaction that can limit clinical effects when taken with Warfarin
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Deoxycholic acid and Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Ardeparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Ardeparin may lead to a major life threatening interaction when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Ardeparin may cause a moderate interaction that could exacerbate diseases when taken with Collagenase clostridium histolyticum and Collagenase clostridium histolyticum may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Ardeparin may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Warfarin
Ardeparin may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Warfarin
Ardeparin (Compound) resembles Fondaparinux (Compound) and Ardeparin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Warfarin |
DB00580 | DB12130 | 311 | 1,017 | [
"DDInter1910",
"DDInter1094"
] | Valdecoxib | Lorlatinib | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
311,
24,
1017
]
],
[
[
311,
24,
175
],
[
175,
24,
1017
]
],
[
[
311,
24,
1421
],
[
1421,
63,
1017
]
],
[
[
311,
25,
629
],
[
629,
24,
1017
]
],
[
[
311,
63,
251
],
[
251,
24,
1017
]
],
[
[
311,
24,
1220
],
[
1220,
25,
1017
]
],
[
[
311,
24,
283
],
[
283,
64,
1017
]
],
[
[
311,
24,
175
],
[
175,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
311,
24,
1421
],
[
1421,
64,
409
],
[
409,
24,
1017
]
],
[
[
311,
24,
126
],
[
126,
23,
271
],
[
271,
23,
1017
]
]
] | [
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Valdecoxib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
]
] | Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Valdecoxib may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Felodipine and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB00867 | DB01222 | 1,052 | 617 | [
"DDInter1606",
"DDInter246"
] | Ritodrine | Budesonide | Adrenergic beta-agonist used to control premature labor. | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with [formoterol]. | Minor | 0 | [
[
[
1052,
23,
617
]
],
[
[
1052,
62,
1351
],
[
1351,
1,
617
]
],
[
[
1052,
23,
1220
],
[
1220,
1,
617
]
],
[
[
1052,
7,
4830
],
[
4830,
46,
617
]
],
[
[
1052,
7,
4507
],
[
4507,
57,
617
]
],
[
[
1052,
24,
1148
],
[
1148,
23,
617
]
],
[
[
1052,
63,
1674
],
[
1674,
23,
617
]
],
[
[
1052,
24,
659
],
[
659,
62,
617
]
],
[
[
1052,
35,
480
],
[
480,
23,
617
]
],
[
[
1052,
24,
392
],
[
392,
63,
617
]
]
] | [
[
[
"Ritodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flunisolide"
],
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} (Compound) upregulates {v} (Gene)",
"TGFBR2"
],
[
"TGFBR2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} (Compound) upregulates {v} (Gene)",
"BMP4"
],
[
"BMP4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
]
] | Ritodrine may cause a minor interaction that can limit clinical effects when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Ritodrine may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Compound)
Ritodrine (Compound) upregulates TGFBR2 (Gene) and TGFBR2 (Gene) is upregulated by Budesonide (Compound)
Ritodrine (Compound) upregulates BMP4 (Gene) and BMP4 (Gene) is downregulated by Budesonide (Compound)
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a minor interaction that can limit clinical effects when taken with Budesonide
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Budesonide
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Budesonide
Ritodrine (Compound) resembles Formoterol (Compound) and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a minor interaction that can limit clinical effects when taken with Budesonide
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Budesonide |
DB00413 | DB00468 | 1,346 | 1,424 | [
"DDInter1505",
"DDInter1557"
] | Pramipexole | Quinine | Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome ( | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood. | Minor | 0 | [
[
[
1346,
23,
1424
]
],
[
[
1346,
6,
8803
],
[
8803,
45,
1424
]
],
[
[
1346,
21,
29316
],
[
29316,
60,
1424
]
],
[
[
1346,
24,
752
],
[
752,
62,
1424
]
],
[
[
1346,
24,
1264
],
[
1264,
63,
1424
]
],
[
[
1346,
6,
8803
],
[
8803,
45,
1422
],
[
1422,
40,
1424
]
],
[
[
1346,
21,
29316
],
[
29316,
60,
11337
],
[
11337,
40,
1424
]
],
[
[
1346,
24,
752
],
[
752,
6,
9752
],
[
9752,
45,
1424
]
],
[
[
1346,
6,
8803
],
[
8803,
45,
752
],
[
752,
62,
1424
]
],
[
[
1346,
24,
820
],
[
820,
21,
29231
],
[
29231,
60,
1424
]
]
] | [
[
[
"Pramipexole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} (Compound) binds {v} (Gene)",
"SLC22A2"
],
[
"SLC22A2",
"{u} (Gene) is bound by {v} (Compound)",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} (Compound) binds {v} (Gene)",
"SLC22A2"
],
[
"SLC22A2",
"{u} (Gene) is bound by {v} (Compound)",
"Quinidine"
],
[
"Quinidine",
"{u} (Compound) resembles {v} (Compound)",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} (Compound) causes {v} (Side Effect)",
"Sweating"
],
[
"Sweating",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinidine barbiturate"
],
[
"Quinidine barbiturate",
"{u} (Compound) resembles {v} (Compound)",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A4"
],
[
"SLC22A4",
"{u} (Gene) is bound by {v} (Compound)",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} (Compound) binds {v} (Gene)",
"SLC22A2"
],
[
"SLC22A2",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Quinine"
]
],
[
[
"Pramipexole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac disorder"
],
[
"Cardiac disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinine"
]
]
] | Pramipexole (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Quinine (Compound)
Pramipexole (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinine (Compound)
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinine
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Pramipexole (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Quinidine (Compound) and Quinidine (Compound) resembles Quinine (Compound)
Pramipexole (Compound) causes Sweating (Side Effect) and Sweating (Side Effect) is caused by Quinidine barbiturate (Compound) and Quinidine barbiturate (Compound) resembles Quinine (Compound)
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine (Compound) binds SLC22A4 (Gene) and SLC22A4 (Gene) is bound by Quinine (Compound)
Pramipexole (Compound) binds SLC22A2 (Gene) and SLC22A2 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Quinine
Pramipexole may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Quinine (Compound) |
DB00366 | DB00593 | 1,594 | 1,464 | [
"DDInter600",
"DDInter695"
] | Doxylamine | Ethosuximide | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Moderate | 1 | [
[
[
1594,
24,
1464
]
],
[
[
1594,
21,
28681
],
[
28681,
60,
1464
]
],
[
[
1594,
24,
401
],
[
401,
63,
1464
]
],
[
[
1594,
24,
1614
],
[
1614,
24,
1464
]
],
[
[
1594,
35,
272
],
[
272,
63,
1464
]
],
[
[
1594,
63,
1242
],
[
1242,
24,
1464
]
],
[
[
1594,
35,
128
],
[
128,
24,
1464
]
],
[
[
1594,
74,
701
],
[
701,
24,
1464
]
],
[
[
1594,
21,
28681
],
[
28681,
60,
1614
],
[
1614,
24,
1464
]
],
[
[
1594,
21,
28725
],
[
28725,
60,
1419
],
[
1419,
63,
1464
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
],
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
],
[
[
"Doxylamine",
"{u} (Compound) causes {v} (Side Effect)",
"Pancytopenia"
],
[
"Pancytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethosuximide"
]
]
] | Doxylamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Ethosuximide (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Nabilone and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine (Compound) resembles Chlorpheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine (Compound) resembles Dexbrompheniramine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine (Compound) resembles Clemastine (Compound) and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide
Doxylamine (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Imatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ethosuximide |
DB00220 | DB08895 | 798 | 976 | [
"DDInter1276",
"DDInter1825"
] | Nelfinavir | Tofacitinib | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Major | 2 | [
[
[
798,
25,
976
]
],
[
[
798,
25,
660
],
[
660,
24,
976
]
],
[
[
798,
25,
214
],
[
214,
63,
976
]
],
[
[
798,
24,
86
],
[
86,
24,
976
]
],
[
[
798,
24,
98
],
[
98,
63,
976
]
],
[
[
798,
63,
1324
],
[
1324,
24,
976
]
],
[
[
798,
24,
1101
],
[
1101,
25,
976
]
],
[
[
798,
25,
39
],
[
39,
25,
976
]
],
[
[
798,
63,
168
],
[
168,
25,
976
]
],
[
[
798,
24,
1619
],
[
1619,
64,
976
]
]
] | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
]
] | Nelfinavir may lead to a major life threatening interaction when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nelfinavir may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Tofacitinib
Nelfinavir may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Tofacitinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Tofacitinib
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may lead to a major life threatening interaction when taken with Tofacitinib |
DB00078 | DB01009 | 1,172 | 935 | [
"DDInter898",
"DDInter1009"
] | Ibritumomab tiuxetan | Ketoprofen | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each. | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Major | 2 | [
[
[
1172,
25,
935
]
],
[
[
1172,
37,
1274
],
[
1274,
24,
935
]
],
[
[
1172,
37,
1263
],
[
1263,
1,
935
]
],
[
[
1172,
24,
282
],
[
282,
40,
935
]
],
[
[
1172,
25,
702
],
[
702,
24,
935
]
],
[
[
1172,
64,
1255
],
[
1255,
24,
935
]
],
[
[
1172,
25,
1046
],
[
1046,
63,
935
]
],
[
[
1172,
24,
1039
],
[
1039,
63,
935
]
],
[
[
1172,
24,
121
],
[
121,
24,
935
]
],
[
[
1172,
25,
365
],
[
365,
64,
935
]
]
] | [
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Bromfenac"
],
[
"Bromfenac",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
],
[
"Nepafenac",
"{u} (Compound) resembles {v} (Compound)",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Urokinase"
],
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketoprofen"
]
]
] | Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Bromfenac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Bromfenac and Bromfenac (Compound) resembles Ketoprofen (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac and Nepafenac (Compound) resembles Ketoprofen (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Urokinase and Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may lead to a major life threatening interaction when taken with Ketoprofen |
DB00563 | DB06317 | 663 | 1,626 | [
"DDInter1174",
"DDInter630"
] | Methotrexate | Elotuzumab | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | Moderate | 1 | [
[
[
663,
24,
1626
]
],
[
[
663,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
663,
24,
200
],
[
200,
63,
1626
]
],
[
[
663,
24,
671
],
[
671,
24,
1626
]
],
[
[
663,
23,
1487
],
[
1487,
24,
1626
]
],
[
[
663,
25,
770
],
[
770,
24,
1626
]
],
[
[
663,
25,
1011
],
[
1011,
64,
1626
]
],
[
[
663,
25,
507
],
[
507,
25,
1626
]
],
[
[
663,
64,
1057
],
[
1057,
25,
1626
]
],
[
[
663,
63,
1463
],
[
1463,
24,
973
],
[
973,
24,
1626
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Methotrexate may cause a minor interaction that can limit clinical effects when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Methotrexate may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Methotrexate may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab
Methotrexate may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Elotuzumab
Methotrexate may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Elotuzumab
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab |
DB00352 | DB06626 | 482 | 263 | [
"DDInter1814",
"DDInter147"
] | Tioguanine | Axitinib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors. Axitinib is an indazole derivative. It is most commonly marketed under the name Inlyta® and is available in oral formulations. | Moderate | 1 | [
[
[
482,
24,
263
]
],
[
[
482,
24,
322
],
[
322,
24,
263
]
],
[
[
482,
24,
1593
],
[
1593,
63,
263
]
],
[
[
482,
63,
1324
],
[
1324,
24,
263
]
],
[
[
482,
23,
839
],
[
839,
24,
263
]
],
[
[
482,
63,
362
],
[
362,
25,
263
]
],
[
[
482,
24,
1236
],
[
1236,
25,
263
]
],
[
[
482,
25,
1377
],
[
1377,
25,
263
]
],
[
[
482,
25,
990
],
[
990,
64,
263
]
],
[
[
482,
24,
384
],
[
384,
64,
263
]
]
] | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Axitinib"
]
]
] | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Axitinib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Axitinib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may lead to a major life threatening interaction when taken with Axitinib
Tioguanine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Axitinib
Tioguanine may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may lead to a major life threatening interaction when taken with Axitinib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Axitinib |
DB00283 | DB00295 | 701 | 475 | [
"DDInter395",
"DDInter1244"
] | Clemastine | Morphine | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Moderate | 1 | [
[
[
701,
24,
475
]
],
[
[
701,
24,
1516
],
[
1516,
1,
475
]
],
[
[
701,
24,
421
],
[
421,
64,
475
]
],
[
[
701,
6,
12523
],
[
12523,
45,
475
]
],
[
[
701,
21,
28784
],
[
28784,
60,
475
]
],
[
[
701,
24,
801
],
[
801,
63,
475
]
],
[
[
701,
35,
1511
],
[
1511,
63,
475
]
],
[
[
701,
63,
1230
],
[
1230,
24,
475
]
],
[
[
701,
24,
1100
],
[
1100,
24,
475
]
],
[
[
701,
25,
306
],
[
306,
63,
475
]
]
] | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Galantamine"
],
[
"Galantamine",
"{u} (Compound) resembles {v} (Compound)",
"Morphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Morphine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Morphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brivaracetam"
],
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
],
[
[
"Clemastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zonisamide"
],
[
"Zonisamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
]
]
] | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Galantamine and Galantamine (Compound) resembles Morphine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone may lead to a major life threatening interaction when taken with Morphine
Clemastine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Morphine (Compound)
Clemastine (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Morphine (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Brivaracetam and Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Clemastine (Compound) resembles Mepenzolate (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Morphine
Clemastine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause a moderate interaction that could exacerbate diseases when taken with Morphine |
DB03904 | DB11110 | 1,574 | 603 | [
"DDInter1903",
"DDInter1115"
] | Urea | Magnesium citrate | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products. | Moderate | 1 | [
[
[
1574,
24,
603
]
],
[
[
1574,
63,
1100
],
[
1100,
24,
603
]
],
[
[
1574,
63,
1100
],
[
1100,
25,
57
],
[
57,
24,
603
]
],
[
[
1574,
63,
355
],
[
355,
23,
16
],
[
16,
23,
603
]
],
[
[
1574,
63,
318
],
[
318,
64,
57
],
[
57,
24,
603
]
],
[
[
1574,
23,
1399
],
[
1399,
62,
964
],
[
964,
24,
603
]
],
[
[
1574,
63,
1100
],
[
1100,
24,
1616
],
[
1616,
24,
603
]
],
[
[
1574,
24,
643
],
[
643,
40,
1100
],
[
1100,
24,
603
]
],
[
[
1574,
23,
1399
],
[
1399,
64,
57
],
[
57,
24,
603
]
],
[
[
1574,
63,
355
],
[
355,
63,
789
],
[
789,
24,
603
]
]
] | [
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
[
"Linaclotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desvenlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
]
] | Urea may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Magnesium citrate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a minor interaction that can limit clinical effects when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine (Compound) resembles Venlafaxine (Compound) and Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate |
DB00242 | DB01284 | 1,064 | 1,042 | [
"DDInter392",
"DDInter1782"
] | Cladribine | Tetracosactide | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Major | 2 | [
[
[
1064,
25,
1042
]
],
[
[
1064,
25,
1683
],
[
1683,
63,
1042
]
],
[
[
1064,
64,
1184
],
[
1184,
24,
1042
]
],
[
[
1064,
24,
1270
],
[
1270,
63,
1042
]
],
[
[
1064,
24,
336
],
[
336,
24,
1042
]
],
[
[
1064,
25,
663
],
[
663,
24,
1042
]
],
[
[
1064,
63,
1245
],
[
1245,
24,
1042
]
],
[
[
1064,
64,
1057
],
[
1057,
25,
1042
]
],
[
[
1064,
25,
1011
],
[
1011,
64,
1042
]
],
[
[
1064,
25,
1377
],
[
1377,
25,
1042
]
]
] | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reserpine"
],
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
]
] | Cladribine may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cladribine may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cladribine may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Reserpine and Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Cladribine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tetracosactide
Cladribine may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tetracosactide
Cladribine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Tetracosactide |
DB00486 | DB01186 | 1,614 | 107 | [
"DDInter1253",
"DDInter1430"
] | Nabilone | Pergolide | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, however it is considered to be twice as active as Δ⁹-THC. Nabilone is approved by the FDA for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in the resin of the marijuana plant, both of which are pharmacologically active due to their interaction with cannabinoid receptors that are | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes. | Moderate | 1 | [
[
[
1614,
24,
107
]
],
[
[
1614,
21,
28757
],
[
28757,
60,
107
]
],
[
[
1614,
24,
832
],
[
832,
24,
107
]
],
[
[
1614,
63,
1594
],
[
1594,
24,
107
]
],
[
[
1614,
24,
1118
],
[
1118,
63,
107
]
],
[
[
1614,
40,
530
],
[
530,
24,
107
]
],
[
[
1614,
21,
28757
],
[
28757,
60,
892
],
[
892,
40,
107
]
],
[
[
1614,
21,
28658
],
[
28658,
60,
588
],
[
588,
1,
107
]
],
[
[
1614,
21,
29027
],
[
29027,
60,
530
],
[
530,
24,
107
]
],
[
[
1614,
21,
29108
],
[
29108,
60,
591
],
[
591,
63,
107
]
]
] | [
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Difenoxin"
],
[
"Difenoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} (Compound) resembles {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cabergoline"
],
[
"Cabergoline",
"{u} (Compound) resembles {v} (Compound)",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Ataxia"
],
[
"Ataxia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Nabilone",
"{u} (Compound) causes {v} (Side Effect)",
"Increased appetite"
],
[
"Increased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ioflupane I-123"
],
[
"Ioflupane I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
]
] | Nabilone (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Pergolide (Compound)
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Difenoxin and Difenoxin may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Nabilone (Compound) resembles Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Nabilone (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Cabergoline (Compound) and Cabergoline (Compound) resembles Pergolide (Compound)
Nabilone (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Methylergometrine (Compound) and Methylergometrine (Compound) resembles Pergolide (Compound)
Nabilone (Compound) causes Ataxia (Side Effect) and Ataxia (Side Effect) is caused by Dronabinol (Compound) and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Nabilone (Compound) causes Increased appetite (Side Effect) and Increased appetite (Side Effect) is caused by Ioflupane I-123 (Compound) and Ioflupane I-123 may cause a moderate interaction that could exacerbate diseases when taken with Pergolide |
DB00026 | DB08870 | 1,184 | 850 | [
"DDInter94",
"DDInter228"
] | Anakinra | Brentuximab vedotin | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after failure of other treatment regimens. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin's lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission. The ECHELON-1 study results demonstrated superior efficacy of the drug combined with a chemotherapy regimen compared to the previous standard of care. Importantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease. | Moderate | 1 | [
[
[
1184,
24,
850
]
],
[
[
1184,
24,
496
],
[
496,
63,
850
]
],
[
[
1184,
24,
611
],
[
611,
24,
850
]
],
[
[
1184,
25,
1583
],
[
1583,
63,
850
]
],
[
[
1184,
25,
980
],
[
980,
24,
850
]
],
[
[
1184,
63,
305
],
[
305,
24,
850
]
],
[
[
1184,
25,
1510
],
[
1510,
64,
850
]
],
[
[
1184,
25,
1377
],
[
1377,
25,
850
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
850
]
],
[
[
1184,
24,
329
],
[
329,
25,
850
]
]
] | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
],
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarilumab"
],
[
"Sarilumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tocilizumab"
],
[
"Tocilizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bleomycin"
],
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
]
]
] | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Dacarbazine and Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Anakinra may lead to a major life threatening interaction when taken with Sarilumab and Sarilumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Anakinra may lead to a major life threatening interaction when taken with Tocilizumab and Tocilizumab may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Anakinra may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Anakinra may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Brentuximab vedotin
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Bleomycin and Bleomycin may lead to a major life threatening interaction when taken with Brentuximab vedotin |
DB08938 | DB14491 | 1,384 | 428 | [
"DDInter1112",
"DDInter725"
] | Magaldrate | Ferrous fumarate | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Used in treatment of iron deficiency anemia. | Moderate | 1 | [
[
[
1384,
24,
428
]
],
[
[
1384,
63,
1096
],
[
1096,
23,
428
]
],
[
[
1384,
62,
752
],
[
752,
23,
428
]
],
[
[
1384,
63,
1008
],
[
1008,
24,
428
]
],
[
[
1384,
24,
133
],
[
133,
24,
428
]
],
[
[
1384,
25,
1436
],
[
1436,
24,
428
]
],
[
[
1384,
62,
1191
],
[
1191,
24,
428
]
],
[
[
1384,
64,
1231
],
[
1231,
24,
428
]
],
[
[
1384,
64,
1459
],
[
1459,
25,
428
]
],
[
[
1384,
25,
627
],
[
627,
25,
428
]
]
] | [
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risedronic acid"
],
[
"Risedronic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baloxavir marboxil"
],
[
"Baloxavir marboxil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
],
[
"Patiromer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tolevamer"
],
[
"Tolevamer",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolutegravir"
],
[
"Dolutegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Magaldrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
],
[
"Bictegravir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ferrous fumarate"
]
]
] | Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Magaldrate may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Risedronic acid and Risedronic acid may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Magaldrate may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil and Baloxavir marboxil may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Magaldrate may lead to a major life threatening interaction when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Magaldrate may cause a minor interaction that can limit clinical effects when taken with Levodopa and Levodopa may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Magaldrate may lead to a major life threatening interaction when taken with Tolevamer and Tolevamer may cause a moderate interaction that could exacerbate diseases when taken with Ferrous fumarate
Magaldrate may lead to a major life threatening interaction when taken with Dolutegravir and Dolutegravir may lead to a major life threatening interaction when taken with Ferrous fumarate
Magaldrate may lead to a major life threatening interaction when taken with Bictegravir and Bictegravir may lead to a major life threatening interaction when taken with Ferrous fumarate |
DB01246 | DB11823 | 820 | 858 | [
"DDInter45",
"DDInter673"
] | Alimemazine | Esketamine | A phenothiazine derivative that is used as an antipruritic. | Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide.[L5596,A175462] On March 5, 2019, the nasal spray drug, _esketamine_, also known as _Spravato_ (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression. Esketamine is the s-enantiomer of [Ketamine]. Ketamine is a mixture of two enantiomers (mirror image molecules). This is the first time that the FDA has approved esketamine for any use. The FDA approved ketamine (Ketalar) in 1970. Esketamine may prove to be a promising treatment for patients diagnosed with major depressive disorder who have not experienced an improvement in symptoms despite treatment with various medications and therapies. The intranasal route of administration for this drug allows for easy administration and a fast onset of action, which sets it apart from many other antidepressant agents that may take several weeks to take effect. | Moderate | 1 | [
[
[
820,
24,
858
]
],
[
[
820,
63,
272
],
[
272,
24,
858
]
],
[
[
820,
74,
1264
],
[
1264,
24,
858
]
],
[
[
820,
1,
104
],
[
104,
24,
858
]
],
[
[
820,
24,
849
],
[
849,
24,
858
]
],
[
[
820,
64,
1311
],
[
1311,
24,
858
]
],
[
[
820,
40,
649
],
[
649,
24,
858
]
],
[
[
820,
63,
73
],
[
73,
25,
858
]
],
[
[
820,
63,
272
],
[
272,
63,
506
],
[
506,
24,
858
]
],
[
[
820,
63,
506
],
[
506,
24,
272
],
[
272,
24,
858
]
]
] | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Clofedanol"
],
[
"Clofedanol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
],
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esketamine"
]
]
] | Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine (Compound) resembles Doxepin (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine may lead to a major life threatening interaction when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine (Compound) resembles Clofedanol (Compound) and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Esketamine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Esketamine
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Esketamine |
DB00008 | DB00193 | 491 | 534 | [
"DDInter1407",
"DDInter1841"
] | Peginterferon alfa-2a | Tramadol | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) resulting in less use of Peginterferon alfa-2a. Peginterferon alfa-2a is derived from the alfa-2a moeity of recombinant human interferon and acts by binding to human type 1 interferon receptors. Activation and dimerization of this receptor induces the body's innate antiviral response by activating the janus kinase | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatment of moderate to severe pain. It is considered a Step 2 option on the World Health Organization's pain ladder and has about 1/10th of the potency of [morphine]. Tramadol differs from other traditional opioid medications in that it doesn't just act as a μ-opioid agonist, but also affects monoamines by modulating the effects of neurotransmitters involved in the modulation of pain such as serotonin and norepinpehrine which activate descending pain inhibitory pathways. Tramadol's effects on serotonin and norepinephrine mimic the effects of other SNRI antidepressants such as [duloxetine] and [venlafaxine]. Tramadol exists as a racemic mixture consisting of two pharmacologically active enantiomers that both contribute to its analgesic property through different mechanisms and are also themselves metabolized into active metabolites: (+)-tramadol and its primary metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the μ opioid receptor while (+)-tramadol inhibits serotonin reuptake and (-)-tramadol inhibits norepinephrine reuptake. These pathways are complementary and synergistic, improving tramadol's ability to modulate the perception of and response to pain.[A4269,A183842] Tramadol has also been shown to affect a number of other pain modulators within the central nervous system as well as non-neuronal inflammatory markers and immune mediators.[A183728,A183734,A183761,A17159,A182300] Due to the broad spectrum of targets involved in pain and inflammation, it's not surprising that the evidence has shown that tramadol is effective for a number of pain types including neuropathic pain, post-operative pain, lower back pain, as well as pain associated with labour, osteoarthritis, fibromyalgia, and cancer. Due to its SNRI activity, tramadol also has anxiolytic, antidepressant, and anti-shivering effects which are all frequently found as comorbidities with pain. Similar to other opioid medications, tramadol poses a risk for development of tolerance, dependence and abuse. If used in higher doses, or with other opioids, there is a dose-related risk of overdose, respiratory depression, and death.[A183830,F4679] However, unlike other opioid medications, tramadol use also carries a risk of seizure and serotonin syndrome, particularly if used with other serotonergic medications.[A183836,A179926] | Major | 2 | [
[
[
491,
25,
534
]
],
[
[
491,
24,
112
],
[
112,
62,
534
]
],
[
[
491,
24,
770
],
[
770,
63,
534
]
],
[
[
491,
25,
976
],
[
976,
63,
534
]
],
[
[
491,
24,
1487
],
[
1487,
64,
534
]
],
[
[
491,
25,
497
],
[
497,
64,
534
]
],
[
[
491,
24,
367
],
[
367,
25,
534
]
],
[
[
491,
24,
112
],
[
112,
62,
1100
],
[
1100,
40,
534
]
],
[
[
491,
24,
770
],
[
770,
63,
1100
],
[
1100,
40,
534
]
],
[
[
491,
25,
976
],
[
976,
25,
760
],
[
760,
63,
534
]
]
] | [
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfacon-1"
],
[
"Interferon alfacon-1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venlafaxine"
],
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
]
]
] | Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Tramadol
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tramadol
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tramadol
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may lead to a major life threatening interaction when taken with Tramadol
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Tramadol
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfacon-1 and Interferon alfacon-1 may lead to a major life threatening interaction when taken with Tramadol
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Venlafaxine and Venlafaxine (Compound) resembles Tramadol (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and Venlafaxine (Compound) resembles Tramadol (Compound)
Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Tramadol |
DB00289 | DB09078 | 847 | 1,228 | [
"DDInter132",
"DDInter1036"
] | Atomoxetine | Lenvatinib | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. These receptor tyrosine kinases (RTKs) located in the cell membrane play a central role in the activation of signal transduction pathways involved in the normal regulation of cellular processes, such as cell proliferation, migration, apoptosis and differentiation, and in pathogenic angiogenesis, lymphogenesis, tumour growth and cancer progression. In particular, VEGF has been identified as a crucial regulator of both physiologic and pathologic angiogenesis and increased expression of VEGF is associated with a poor prognosis in many types of cancers. Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer. Most patients with thyroid cancer have a very good prognosis with treatment (98% 5 year survival rate) involving surgery and hormone therapy. However, for patients with RAI-refractory thyroid cancer, treatment options are limited and the prognosis is poor, leading to a push for the development of more targeted therapies such as lenvatinib. | Moderate | 1 | [
[
[
847,
24,
1228
]
],
[
[
847,
23,
112
],
[
112,
23,
1228
]
],
[
[
847,
24,
609
],
[
609,
24,
1228
]
],
[
[
847,
23,
1264
],
[
1264,
24,
1228
]
],
[
[
847,
24,
603
],
[
603,
63,
1228
]
],
[
[
847,
63,
912
],
[
912,
24,
1228
]
],
[
[
847,
1,
371
],
[
371,
24,
1228
]
],
[
[
847,
25,
1069
],
[
1069,
25,
1228
]
],
[
[
847,
25,
982
],
[
982,
64,
1228
]
],
[
[
847,
64,
702
],
[
702,
25,
1228
]
]
] | [
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Propafenone"
],
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Atomoxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
]
] | Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Atomoxetine may cause a minor interaction that can limit clinical effects when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Atomoxetine (Compound) resembles Propafenone (Compound) and Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib
Atomoxetine may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Lenvatinib
Atomoxetine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Lenvatinib
Atomoxetine may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Lenvatinib |
DB06589 | DB06595 | 1,250 | 1,491 | [
"DDInter1400",
"DDInter1214"
] | Pazopanib | Midostaurin | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Moderate | 1 | [
[
[
1250,
24,
1491
]
],
[
[
1250,
23,
1135
],
[
1135,
62,
1491
]
],
[
[
1250,
62,
112
],
[
112,
23,
1491
]
],
[
[
1250,
63,
761
],
[
761,
24,
1491
]
],
[
[
1250,
24,
1017
],
[
1017,
63,
1491
]
],
[
[
1250,
64,
1424
],
[
1424,
24,
1491
]
],
[
[
1250,
25,
351
],
[
351,
63,
1491
]
],
[
[
1250,
62,
479
],
[
479,
24,
1491
]
],
[
[
1250,
35,
786
],
[
786,
63,
1491
]
],
[
[
1250,
64,
1377
],
[
1377,
25,
1491
]
]
] | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
]
] | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Pazopanib may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Pazopanib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Pazopanib may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Pazopanib (Compound) resembles Rilpivirine (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin
Pazopanib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Midostaurin |
DB00327 | DB00662 | 421 | 717 | [
"DDInter890",
"DDInter1873"
] | Hydromorphone | Trimethobenzamide | Hydromorphone is a pure opioid, a semi-synthetic hydrogenated ketone derivative of [morphine] that has been available clinically since 1920. Structurally, hydromorphone derived from [morphine] in the modification of the hydroxyl group in the carbon 6 to a carbonyl and the absence of a double bond between the carbon 7 and 8. Due to these modifications, it presents a very high potency and comparable side effect profile to the parent compound. Even though hydromorphone does not present a 6-hydroxyl group, it is categorized under the family of phenanthrenes and it is considered a chemical under the schedule II (medical purposes with high addiction potential). The first reported approved product containing hydromorphone in the form of hydromorphone hydrochloride was developed by Fresenius Kabi USA and FDA approved in 1984. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. | Moderate | 1 | [
[
[
421,
24,
717
]
],
[
[
421,
21,
29648
],
[
29648,
60,
717
]
],
[
[
421,
24,
1594
],
[
1594,
24,
717
]
],
[
[
421,
1,
314
],
[
314,
63,
717
]
],
[
[
421,
24,
1376
],
[
1376,
63,
717
]
],
[
[
421,
1,
828
],
[
828,
24,
717
]
],
[
[
421,
40,
993
],
[
993,
63,
717
]
],
[
[
421,
64,
475
],
[
475,
24,
717
]
],
[
[
421,
63,
701
],
[
701,
24,
717
]
],
[
[
421,
21,
29648
],
[
29648,
60,
1382
],
[
1382,
63,
717
]
]
] | [
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Diamorphine"
],
[
"Diamorphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Hydromorphone",
"{u} (Compound) causes {v} (Side Effect)",
"Disorientation"
],
[
"Disorientation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
]
] | Hydromorphone (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Trimethobenzamide (Compound)
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone (Compound) resembles Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone (Compound) resembles Diamorphine (Compound) and Diamorphine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Hydromorphone (Compound) causes Disorientation (Side Effect) and Disorientation (Side Effect) is caused by Midazolam (Compound) and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide |
DB01599 | DB09082 | 1,232 | 659 | [
"DDInter1523",
"DDInter1934"
] | Probucol | Vilanterol | A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993). | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
1232,
24,
659
]
],
[
[
1232,
24,
927
],
[
927,
63,
659
]
],
[
[
1232,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1232,
63,
485
],
[
485,
24,
659
]
],
[
[
1232,
24,
129
],
[
129,
24,
659
]
],
[
[
1232,
64,
702
],
[
702,
24,
659
]
],
[
[
1232,
25,
982
],
[
982,
63,
659
]
],
[
[
1232,
25,
877
],
[
877,
64,
659
]
],
[
[
1232,
24,
927
],
[
927,
64,
1220
],
[
1220,
23,
659
]
],
[
[
1232,
25,
1069
],
[
1069,
63,
1220
],
[
1220,
23,
659
]
]
] | [
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Probucol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
]
] | Probucol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Probucol may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Probucol may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Probucol may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Probucol may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol
Probucol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Probucol may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB00015 | DB05578 | 582 | 330 | [
"DDInter1585",
"DDInter1566"
] | Reteplase | Ramucirumab | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucirumab is indicated for us in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy. | Major | 2 | [
[
[
582,
25,
330
]
],
[
[
582,
24,
41
],
[
41,
63,
330
]
],
[
[
582,
24,
901
],
[
901,
24,
330
]
],
[
[
582,
24,
1317
],
[
1317,
25,
330
]
],
[
[
582,
25,
1468
],
[
1468,
64,
330
]
],
[
[
582,
25,
1564
],
[
1564,
25,
330
]
],
[
[
582,
24,
972
],
[
972,
64,
330
]
],
[
[
582,
64,
942
],
[
942,
25,
330
]
],
[
[
582,
24,
1274
],
[
1274,
37,
330
]
],
[
[
582,
24,
41
],
[
41,
25,
384
],
[
384,
63,
330
]
]
] | [
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dipyridamole"
],
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Choline salicylate"
],
[
"Choline salicylate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramucirumab"
]
]
] | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Dipyridamole and Dipyridamole may lead to a major life threatening interaction when taken with Ramucirumab
Reteplase may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Ramucirumab
Reteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may lead to a major life threatening interaction when taken with Ramucirumab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate and Choline salicylate may lead to a major life threatening interaction when taken with Ramucirumab
Reteplase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may lead to a major life threatening interaction when taken with Ramucirumab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab and Flurbiprofen may lead to a major life threatening interaction when taken with Ramucirumab
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ramucirumab |
DB00747 | DB01238 | 1,442 | 673 | [
"DDInter1647",
"DDInter118"
] | Scopolamine | Aripiprazole | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient than extracting scopolamine from plants. As an acetylcholine analogue, scopolamine can antagonize muscarinic acetylcholine receptors (mAChRs) in the central nervous system and throughout the body, inducing several therapeutic and adverse effects related to alteration of parasympathetic nervous system and cholinergic signalling.[A228758, L31578] Due to its dose-dependent adverse effects, scopolamine was the first drug to be offered commercially as a transdermal delivery system, Scopoderm TTS®, in 1981.[A228423, | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Moderate | 1 | [
[
[
1442,
24,
673
]
],
[
[
1442,
24,
1630
],
[
1630,
1,
673
]
],
[
[
1442,
6,
4304
],
[
4304,
45,
673
]
],
[
[
1442,
21,
28740
],
[
28740,
60,
673
]
],
[
[
1442,
24,
537
],
[
537,
24,
673
]
],
[
[
1442,
24,
830
],
[
830,
63,
673
]
],
[
[
1442,
63,
1425
],
[
1425,
24,
673
]
],
[
[
1442,
74,
85
],
[
85,
24,
673
]
],
[
[
1442,
63,
475
],
[
475,
25,
673
]
],
[
[
1442,
24,
1311
],
[
1311,
25,
673
]
]
] | [
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} (Compound) causes {v} (Side Effect)",
"Disturbance in attention"
],
[
"Disturbance in attention",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
],
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aripiprazole"
]
],
[
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aripiprazole"
]
]
] | Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Scopolamine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Aripiprazole (Compound)
Scopolamine (Compound) causes Disturbance in attention (Side Effect) and Disturbance in attention (Side Effect) is caused by Aripiprazole (Compound)
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Cisapride and Cisapride may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Scopolamine (Compound) resembles Atropine (Compound) and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Aripiprazole
Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Aripiprazole |
DB00526 | DB00557 | 1,555 | 252 | [
"DDInter1355",
"DDInter895"
] | Oxaliplatin | Hydroxyzine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of the chloride moieties. Due to this chemical moiety, oxaliplatin readily undergoes non-enzymatic biotransformation, thus complicating oxaliplatin's pharmacokinetics. Like most platinum-based compounds, oxaliplatin's mechanism of action is primarily through DNA damage through DNA crosslinking, particularly intrastrand and interstrand crosslinking. However, due to the structure of oxaliplatin, its adducts make the binding of mismatch repair protein to DNA harder compared to cisplatin or carboplatin's adducts, resulting in greater cytotoxic effects. The | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Moderate | 1 | [
[
[
1555,
24,
252
]
],
[
[
1555,
24,
1630
],
[
1630,
1,
252
]
],
[
[
1555,
24,
623
],
[
623,
40,
252
]
],
[
[
1555,
24,
112
],
[
112,
62,
252
]
],
[
[
1555,
63,
1181
],
[
1181,
24,
252
]
],
[
[
1555,
24,
820
],
[
820,
63,
252
]
],
[
[
1555,
25,
770
],
[
770,
63,
252
]
],
[
[
1555,
25,
877
],
[
877,
64,
252
]
],
[
[
1555,
64,
702
],
[
702,
25,
252
]
],
[
[
1555,
25,
11
],
[
11,
25,
252
]
]
] | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Oxaliplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
]
] | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Hydroxyzine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound)
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Hydroxyzine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Oxaliplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine
Oxaliplatin may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Hydroxyzine
Oxaliplatin may lead to a major life threatening interaction when taken with Anagrelide and Anagrelide may lead to a major life threatening interaction when taken with Hydroxyzine
Oxaliplatin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Hydroxyzine |
DB01059 | DB01362 | 956 | 497 | [
"DDInter1313",
"DDInter960"
] | Norfloxacin | Iohexol | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
956,
25,
497
]
],
[
[
956,
18,
7744
],
[
7744,
57,
497
]
],
[
[
956,
21,
28681
],
[
28681,
60,
497
]
],
[
[
956,
64,
891
],
[
891,
25,
497
]
],
[
[
956,
24,
1264
],
[
1264,
25,
497
]
],
[
[
956,
40,
246
],
[
246,
25,
497
]
],
[
[
956,
24,
129
],
[
129,
64,
497
]
],
[
[
956,
63,
1010
],
[
1010,
25,
497
]
],
[
[
956,
62,
372
],
[
372,
25,
497
]
],
[
[
956,
23,
1532
],
[
1532,
25,
497
]
]
] | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} (Compound) downregulates {v} (Gene)",
"PRR7"
],
[
"PRR7",
"{u} (Gene) is downregulated by {v} (Compound)",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] | Norfloxacin (Compound) downregulates PRR7 (Gene) and PRR7 (Gene) is downregulated by Iohexol (Compound)
Norfloxacin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Norfloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Iohexol
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Iohexol
Norfloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Iohexol
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Iohexol
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may lead to a major life threatening interaction when taken with Iohexol
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iohexol
Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Iohexol |
DB00674 | DB08881 | 1,516 | 868 | [
"DDInter802",
"DDInter1925"
] | Galantamine | Vemurafenib | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Moderate | 1 | [
[
[
1516,
24,
868
]
],
[
[
1516,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1516,
7,
2635
],
[
2635,
46,
868
]
],
[
[
1516,
18,
15501
],
[
15501,
57,
868
]
],
[
[
1516,
21,
28847
],
[
28847,
60,
868
]
],
[
[
1516,
24,
112
],
[
112,
23,
868
]
],
[
[
1516,
24,
760
],
[
760,
63,
868
]
],
[
[
1516,
24,
1376
],
[
1376,
24,
868
]
],
[
[
1516,
63,
1419
],
[
1419,
24,
868
]
],
[
[
1516,
1,
828
],
[
828,
24,
868
]
]
] | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} (Compound) upregulates {v} (Gene)",
"MYLK"
],
[
"MYLK",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} (Compound) downregulates {v} (Gene)",
"CCDC86"
],
[
"CCDC86",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Galantamine",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] | Galantamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Galantamine (Compound) upregulates MYLK (Gene) and MYLK (Gene) is upregulated by Vemurafenib (Compound)
Galantamine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Vemurafenib (Compound)
Galantamine (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Galantamine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB01309 | DB04861 | 1,254 | 1,592 | [
"DDInter933",
"DDInter1271"
] | Insulin glulisine | Nebivolol | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being | Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics. Nebivolol was granted FDA approval on 17 December 2007. | Moderate | 1 | [
[
[
1254,
24,
1592
]
],
[
[
1254,
63,
1479
],
[
1479,
23,
1592
]
],
[
[
1254,
24,
1450
],
[
1450,
63,
1592
]
],
[
[
1254,
63,
1445
],
[
1445,
24,
1592
]
],
[
[
1254,
24,
22
],
[
22,
24,
1592
]
],
[
[
1254,
63,
1479
],
[
1479,
21,
28695
],
[
28695,
60,
1592
]
],
[
[
1254,
63,
417
],
[
417,
24,
115
],
[
115,
62,
1592
]
],
[
[
1254,
24,
1450
],
[
1450,
63,
417
],
[
417,
23,
1592
]
],
[
[
1254,
24,
1476
],
[
1476,
63,
578
],
[
578,
62,
1592
]
],
[
[
1254,
63,
1445
],
[
1445,
6,
3576
],
[
3576,
45,
1592
]
]
] | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Nebivolol"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"ADRB2"
],
[
"ADRB2",
"{u} (Gene) is bound by {v} (Compound)",
"Nebivolol"
]
]
] | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Nebivolol (Compound)
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nebivolol
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Nebivolol (Compound) |
DB01206 | DB10315 | 37 | 1,137 | [
"DDInter1086",
"DDInter1127"
] | Lomustine | Measles virus vaccine live attenuated | An alkylating agent of value against both hematologic malignancies and solid tumors. | Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture. | Major | 2 | [
[
[
37,
25,
1137
]
],
[
[
37,
64,
581
],
[
581,
25,
1137
]
],
[
[
37,
24,
384
],
[
384,
25,
1137
]
],
[
[
37,
63,
1184
],
[
1184,
25,
1137
]
],
[
[
37,
25,
676
],
[
676,
64,
1137
]
],
[
[
37,
25,
375
],
[
375,
25,
1137
]
],
[
[
37,
74,
552
],
[
552,
25,
1137
]
],
[
[
37,
24,
738
],
[
738,
64,
1137
]
],
[
[
37,
62,
147
],
[
147,
25,
1137
]
],
[
[
37,
64,
581
],
[
581,
25,
1042
],
[
1042,
24,
1137
]
]
] | [
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
]
],
[
[
"Lomustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Measles virus vaccine live attenuated"
]
]
] | Lomustine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine (Compound) resembles Carmustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated
Lomustine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Measles virus vaccine live attenuated |
DB00731 | DB06343 | 1,144 | 1,379 | [
"DDInter1269",
"DDInter1766"
] | Nateglinide | Teprotumumab | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by the FDA in January 2020 for the treatment of TED. Thyroid eye disease is a potentially debilitating complication of Graves' Disease involving inflammation and tissue remodeling behind the eye, and previous treatment options typically involved multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease. | Moderate | 1 | [
[
[
1144,
24,
1379
]
],
[
[
1144,
24,
959
],
[
959,
24,
1379
]
],
[
[
1144,
24,
1450
],
[
1450,
63,
1379
]
],
[
[
1144,
63,
590
],
[
590,
24,
1379
]
],
[
[
1144,
24,
959
],
[
959,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
1144,
63,
590
],
[
590,
24,
1296
],
[
1296,
63,
1379
]
],
[
[
1144,
24,
433
],
[
433,
63,
1296
],
[
1296,
63,
1379
]
],
[
[
1144,
62,
1103
],
[
1103,
23,
1296
],
[
1296,
63,
1379
]
],
[
[
1144,
24,
959
],
[
959,
24,
1254
],
[
1254,
24,
1379
]
],
[
[
1144,
24,
170
],
[
170,
63,
959
],
[
959,
24,
1379
]
]
] | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
],
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Teprotumumab"
]
]
] | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Teprotumumab |
DB08870 | DB12035 | 850 | 943 | [
"DDInter228",
"DDInter1641"
] | Brentuximab vedotin | Sarecycline | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodg | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993, A39994] the US Food and Drug Administration approved Barcelona based Almirall, S.A.'s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients nine years of age and older . Seysara (sarecycline) was originally part of Allergan's US Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a means of consolidating and reinforcing the dermatology-focused pharmaceutical company's presence in the United States . Acne vulgaris itself is a common chronic skin condition associated with the blockage and/or inflammation of hair follicles and their accompanying sebaceous glands . The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well . Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental scarring resulting from cases of severe acne . Subsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more specific spectrum of antibacterial activity, resulting in fewer off-target antibacterial effects on endogenous intestinal flora and consequently fewer resultant adverse effects associated with diarrhea, fungal overgrowth, etc. | Moderate | 1 | [
[
[
850,
24,
943
]
],
[
[
850,
24,
1670
],
[
1670,
24,
943
]
],
[
[
850,
63,
1668
],
[
1668,
24,
943
]
],
[
[
850,
24,
971
],
[
971,
63,
943
]
],
[
[
850,
63,
640
],
[
640,
25,
943
]
],
[
[
850,
24,
1670
],
[
1670,
23,
1135
],
[
1135,
23,
943
]
],
[
[
850,
63,
1668
],
[
1668,
24,
1670
],
[
1670,
24,
943
]
],
[
[
850,
24,
1281
],
[
1281,
24,
971
],
[
971,
63,
943
]
],
[
[
850,
63,
392
],
[
392,
23,
1135
],
[
1135,
23,
943
]
],
[
[
850,
63,
309
],
[
309,
63,
147
],
[
147,
24,
943
]
]
] | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sarecycline"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
]
] | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Acitretin and Acitretin may lead to a major life threatening interaction when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Sarecycline
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline |
DB06448 | DB12332 | 171 | 1,619 | [
"DDInter1087",
"DDInter1626"
] | Lonafarnib | Rucaparib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FT | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Major | 2 | [
[
[
171,
25,
1619
]
],
[
[
171,
62,
222
],
[
222,
23,
1619
]
],
[
[
171,
63,
112
],
[
112,
23,
1619
]
],
[
[
171,
25,
1135
],
[
1135,
23,
1619
]
],
[
[
171,
63,
309
],
[
309,
24,
1619
]
],
[
[
171,
64,
1419
],
[
1419,
24,
1619
]
],
[
[
171,
25,
1019
],
[
1019,
24,
1619
]
],
[
[
171,
24,
738
],
[
738,
24,
1619
]
],
[
[
171,
25,
159
],
[
159,
63,
1619
]
],
[
[
171,
24,
466
],
[
466,
63,
1619
]
]
] | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Lonafarnib may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lonafarnib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lonafarnib may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lonafarnib may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00418 | DB05676 | 536 | 1,513 | [
"DDInter1650",
"DDInter111"
] | Secobarbital | Apremilast | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July 2019, apremilast was granted a new FDA approval for the treatment of oral ulcers associated with Behcet's disease, an autoimmune condition that causes recurrent skin, blood vessel, and central nervous system inflammation. | Moderate | 1 | [
[
[
536,
24,
1513
]
],
[
[
536,
62,
1101
],
[
1101,
24,
1513
]
],
[
[
536,
40,
288
],
[
288,
24,
1513
]
],
[
[
536,
24,
971
],
[
971,
63,
1513
]
],
[
[
536,
63,
353
],
[
353,
24,
1513
]
],
[
[
536,
24,
1220
],
[
1220,
24,
1513
]
],
[
[
536,
24,
129
],
[
129,
64,
1513
]
],
[
[
536,
40,
697
],
[
697,
25,
1513
]
],
[
[
536,
62,
1101
],
[
1101,
24,
307
],
[
307,
23,
1513
]
],
[
[
536,
40,
288
],
[
288,
23,
1101
],
[
1101,
24,
1513
]
]
] | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
],
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apremilast"
]
],
[
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Butalbital"
],
[
"Butalbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apremilast"
]
]
] | Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Secobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Apremilast
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Apremilast
Secobarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may lead to a major life threatening interaction when taken with Apremilast
Secobarbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Apremilast
Secobarbital (Compound) resembles Butalbital (Compound) and Butalbital may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Apremilast |
DB01193 | DB06709 | 819 | 592 | [
"DDInter12",
"DDInter1165"
] | Acebutolol | Methacholine | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Asthma is a complex condition associated with phenomena such as airway hyperresponsiveness (AHR), in which the smooth muscle in the airways (ASM) excessively contracts in response to stimuli, reducing pulmonary function and causing symptoms such as difficulty breathing.[A229598, A229603] Although the underlying pathology of AHR is complex, ASM contraction can be stimulated by cholinergic agonists that activate M<sub>3</sub> muscarinic receptors that stimulate ASM contraction.[A229603, A229618, A229643] Methacholine is a non-specific cholinergic agonist (parasympathomimetic) that acts through muscarinic receptors in the lungs to induce bronchoconstriction. In patients with AHR, a lower dose of methacholine is required to induce bronchoconstriction, which forms the basis for the methacholine challenge test to diagnose AHR.[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc. | Major | 2 | [
[
[
819,
25,
592
]
],
[
[
819,
21,
28644
],
[
28644,
60,
592
]
],
[
[
819,
40,
88
],
[
88,
25,
592
]
],
[
[
819,
21,
28644
],
[
28644,
60,
668
],
[
668,
25,
592
]
],
[
[
819,
21,
28722
],
[
28722,
60,
427
],
[
427,
40,
592
]
],
[
[
819,
40,
88
],
[
88,
21,
28644
],
[
28644,
60,
592
]
],
[
[
819,
63,
1442
],
[
1442,
24,
427
],
[
427,
40,
592
]
],
[
[
819,
63,
1442
],
[
1442,
6,
4304
],
[
4304,
45,
592
]
],
[
[
819,
63,
1528
],
[
1528,
21,
28722
],
[
28722,
60,
592
]
],
[
[
819,
40,
887
],
[
887,
1,
668
],
[
668,
25,
592
]
]
] | [
[
[
"Acebutolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levobunolol"
],
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bethanechol"
],
[
"Bethanechol",
"{u} (Compound) resembles {v} (Compound)",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bethanechol"
],
[
"Bethanechol",
"{u} (Compound) resembles {v} (Compound)",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
],
[
"Scopolamine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
],
[
"Physostigmine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methacholine"
]
],
[
[
"Acebutolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
],
[
"Levobunolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methacholine"
]
]
] | Acebutolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Methacholine (Compound)
Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol may lead to a major life threatening interaction when taken with Methacholine
Acebutolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Levobunolol (Compound) and Levobunolol may lead to a major life threatening interaction when taken with Methacholine
Acebutolol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Bethanechol (Compound) and Bethanechol (Compound) resembles Methacholine (Compound)
Acebutolol (Compound) resembles Metoprolol (Compound) and Metoprolol (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Methacholine (Compound)
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine may cause a moderate interaction that could exacerbate diseases when taken with Bethanechol and Bethanechol (Compound) resembles Methacholine (Compound)
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine and Scopolamine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Methacholine (Compound)
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Methacholine (Compound)
Acebutolol (Compound) resembles Pindolol (Compound) and Pindolol (Compound) resembles Levobunolol (Compound) and Levobunolol may lead to a major life threatening interaction when taken with Methacholine |
DB01076 | DB08871 | 700 | 36 | [
"DDInter133",
"DDInter666"
] | Atorvastatin | Eribulin | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors . | Moderate | 1 | [
[
[
700,
24,
36
]
],
[
[
700,
63,
1488
],
[
1488,
24,
36
]
],
[
[
700,
24,
973
],
[
973,
24,
36
]
],
[
[
700,
25,
609
],
[
609,
24,
36
]
],
[
[
700,
40,
671
],
[
671,
24,
36
]
],
[
[
700,
64,
600
],
[
600,
24,
36
]
],
[
[
700,
24,
384
],
[
384,
63,
36
]
],
[
[
700,
23,
286
],
[
286,
63,
36
]
],
[
[
700,
25,
1510
],
[
1510,
64,
36
]
],
[
[
700,
24,
1593
],
[
1593,
25,
36
]
]
] | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eribulin"
]
]
] | Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Atorvastatin may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Eribulin
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Eribulin |
DB01225 | DB01404 | 500 | 757 | [
"DDInter645",
"DDInter820"
] | Enoxaparin | Ginseng | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding.[A228178,A228313] | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
500,
24,
757
]
],
[
[
500,
64,
25
],
[
25,
24,
757
]
],
[
[
500,
25,
578
],
[
578,
63,
757
]
],
[
[
500,
64,
25
],
[
25,
24,
578
],
[
578,
63,
757
]
],
[
[
500,
25,
578
],
[
578,
63,
25
],
[
25,
24,
757
]
],
[
[
500,
64,
553
],
[
553,
64,
25
],
[
25,
24,
757
]
],
[
[
500,
25,
256
],
[
256,
64,
25
],
[
25,
24,
757
]
],
[
[
500,
64,
1347
],
[
1347,
62,
245
],
[
245,
24,
757
]
],
[
[
500,
64,
126
],
[
126,
63,
245
],
[
245,
24,
757
]
],
[
[
500,
64,
1578
],
[
1578,
25,
25
],
[
25,
24,
757
]
]
] | [
[
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Enoxaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anistreplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
]
] | Enoxaparin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Enoxaparin may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Ginseng |
DB00470 | DB00774 | 530 | 1,577 | [
"DDInter601",
"DDInter889"
] | Dronabinol | Hydroflumethiazide | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
530,
24,
1577
]
],
[
[
530,
24,
359
],
[
359,
40,
1577
]
],
[
[
530,
63,
323
],
[
323,
40,
1577
]
],
[
[
530,
24,
504
],
[
504,
1,
1577
]
],
[
[
530,
21,
29209
],
[
29209,
60,
1577
]
],
[
[
530,
63,
475
],
[
475,
24,
1577
]
],
[
[
530,
24,
849
],
[
849,
63,
1577
]
],
[
[
530,
25,
593
],
[
593,
63,
1577
]
],
[
[
530,
1,
1614
],
[
1614,
24,
1577
]
],
[
[
530,
24,
359
],
[
359,
40,
504
],
[
504,
1,
1577
]
]
] | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} (Compound) resembles {v} (Compound)",
"Nabilone"
],
[
"Nabilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
]
] | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles Hydroflumethiazide (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Dronabinol (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Hydroflumethiazide (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Dronabinol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydrochlorothiazide (Compound) and Hydrochlorothiazide (Compound) resembles Hydroflumethiazide (Compound) |
DB00530 | DB00564 | 1,195 | 1,236 | [
"DDInter667",
"DDInter293"
] | Erlotinib | Carbamazepine | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder. | Moderate | 1 | [
[
[
1195,
24,
1236
]
],
[
[
1195,
23,
307
],
[
307,
1,
1236
]
],
[
[
1195,
63,
362
],
[
362,
1,
1236
]
],
[
[
1195,
24,
1335
],
[
1335,
40,
1236
]
],
[
[
1195,
6,
3486
],
[
3486,
45,
1236
]
],
[
[
1195,
7,
1700
],
[
1700,
46,
1236
]
],
[
[
1195,
18,
4360
],
[
4360,
57,
1236
]
],
[
[
1195,
21,
28864
],
[
28864,
60,
1236
]
],
[
[
1195,
63,
1101
],
[
1101,
23,
1236
]
],
[
[
1195,
63,
322
],
[
322,
24,
1236
]
]
] | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} (Compound) upregulates {v} (Gene)",
"SIRT3"
],
[
"SIRT3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} (Compound) downregulates {v} (Gene)",
"TIMM9"
],
[
"TIMM9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema multiforme"
],
[
"Erythema multiforme",
"{u} (Side Effect) is caused by {v} (Compound)",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Carbamazepine"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbamazepine"
]
]
] | Erlotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) resembles Carbamazepine (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Carbamazepine (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Carbamazepine (Compound)
Erlotinib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Carbamazepine (Compound)
Erlotinib (Compound) upregulates SIRT3 (Gene) and SIRT3 (Gene) is upregulated by Carbamazepine (Compound)
Erlotinib (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Carbamazepine (Compound)
Erlotinib (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Carbamazepine (Compound)
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Carbamazepine
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.